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Abstract 
Besides typical characteristics of cellular senescence such as cell cycle arrest and increased SA β-
gal (senescence-associated β-galactosidase) activity, the aging process of primary human 
mammary epithelial cells (HMEC) was accompanied by significant alterations of the extracellular 
environment, involving cell-cell and cell-matrix interactions. Expression of the cell surface-
associated glycoproteins CD24, CD44 and CD227 (MUC1) was significantly reduced upon 
senescence, whereas these proteins were overexpressed in MCF-7 breast cancer cells. Analysis of 
different matrix metalloproteinases (MMPs) revealed a significant down-regulation of latent and 
active MMP-7 in senescent HMEC in contrast to the unchanged protein levels of MMP-1, MMP-
2 and MMP-9. Down-modulation of MMP-7 by RNAi in young HMEC P12 implicated an 
accelerated aging and verified an essential role of MMP-7 for HMEC senescence, whereas no 
comparable effect was detectable in MCF-7 breast cancer cells.  
Concomitant with an enhanced expression of the elastin precursor protein tropoelastin in 
senescent HMEC populations, the formation of elastin-like structures was observed. This was, 
moreover, paralleled by elevated lysyl oxidase-like 1 (LOXL1) levels and an increased lysyl 
oxidase (LO) activity. RNAi of MMP-7 identified a direct relation between reduced MMP-7 
activity and an induction of tropoelastin expression, involving down-regulation of the 
transcription factor Fra-1. Similar effects were provoked upon impaired heparin-binding 
epidermal growth factor-like growth factor (HB-EGF) signaling, also causing a decline of Fra-1 
levels followed by activation of tropoelastin synthesis. In addition, down-modulation of HB-EGF 
was associated with an elevated LOX activity as well as increased cell death and aberrant mitosis. 
Immunofluorescence studies revealed co-localization of MMP-7 and HB-EGF to be restricted to 
young HMEC, whereas their distribution differed significantly in senescent HMEC, and MMP-7 
demonstrated a distinct nuclear localization.  
Clearly, the extracellular proteinase MMP-7 is an important factor involved in an accelerated 
aging process of HMEC. It is suggested that the decreased activity of MMP-7 affects ectodomain 
shedding of HB-EGF in senescent HMEC and thereby inhibits intracellular signaling via Fra-1. 
As Fra-1 functions as a repressor of tropoelastin transcription, attenuated MMP-7 activity 
eventually initiates an increased tropoelastin synthesis and contributes to an enhanced 
extracellular formation of elastin-like structures during cellular senescence of HMEC. 
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Zusammenfassung 
Im Zuge der zellulären Seneszenz verlieren humane Mammaepithelzellen (HMEC) ihre Fähigkeit 
sich zu teilen, arretieren im Zellzyklus und zeigen eine erhöhte SA β-gal (senescence-associated β-
galactosidase) Aktivität. Darüber hinaus war der Alterungsprozess der HMEC mit deutlichen 
Veränderungen ihrer extrazellulären Umgebung verbunden, die wiederum Einfluss auf Zell-Zell- 
sowie Zell-Matrix-Wechselwirkungen nimmt. So sank die Expression der Zelloberflächen-
Glykoproteine CD24, CD44 und CD277 (MUC1) in seneszenten HMEC, während die 
Brustkrebszelllinie MCF-7 eine Überexpression dieser Proteine zeigte. Bei der Untersuchung 
verschiedener Matrixmetalloproteinasen während der HMEC-Alterung fiel eine drastische 
Reduktion von MMP-7 gegenüber einer gleichbleibenden Expression von MMP-1, MMP-2 und 
MMP-9 auf. Die Herunterregulation von MMP-7 in jungen HMEC P12 mittels siRNA induzierte 
eine stark beschleunigte Alterung, wohingegen keine vergleichbaren Effekte infolge MMP-7 
RNAi in den immortalisierten MCF-7 festgestellt werden konnten. Dies ließ eine essentielle Rolle 
von MMP-7 während der zellulären Seneszenz primärer HMEC vermuten. 
Des Weiteren wurde eine erhöhte Expression des Elastin-Vorläuferproteins Tropoelastin in 
gealterten HMEC nachgewiesen, die wiederum mit vermehrtem LOXL1 (lysyl oxidase-like-1) 
und einer gesteigerten Lysyloxidase-Aktivität sowie der extrazellulären Bildung Elastin-ähnlicher 
Fasern einherging. Ein weiterer siRNA-Ansatz bestätigte einen direkten Zusammenhang 
zwischen der verminderten MMP-7-Aktivität und einer Induktion der Tropoelastin-Synthese, 
wobei unter anderem der Transkriptionsfaktor Fra-1 involviert war. Eine vergleichbare 
Tropoelastin-Aktivierung, unter Einbezug reduzierter Fra-1-Level, wurde auch infolge einer 
siRNA-vermittelten Herunterregulation von HB-EGF (heparin-binding epidermal growth factor-
like growth factor) in jungen HMEC bewirkt. Darüber hinaus wurde eine erhöhte LOX-Aktivität 
induziert und die verminderte HB-EGF-Expression war mit vermehrtem Zelltod bzw. 
unnatürlichen Mitosen ohne Zellteilung verbunden. Mittels Immunfluoreszenzanalysen wurde 
eine Co-Lokalisation von MMP-7 und HB-EGF in jungen HMEC festgestellt. In seneszenten 
HMEC unterschied sich die Verteilung der MMP-7 jedoch deutlich von der des HB-EGF und 
eine vorwiegend nukleäre MMP-7-Lokalisation fiel auf. 
Diese Arbeit kennzeichnet MMP-7 als einen essentiellen Faktor im Rahmen der zellulären 
Seneszenz von HMEC und zeigt einen beschleunigten Alterungsprozess aufgrund verminderter 
MMP-7-Expression. Zudem vermag eine reduzierte MMP-7-Aktivität die extrazelluläre Spaltung 
von HB-EGF beeinflussen, was sich hingegen negativ auf die Aktivierung von Fra-1 auswirkt. Da 
Fra-1 als Repressor der Tropoelastin-Transkription fungiert, würde eine beeinträchtigte MMP-7-
Aktivität die Induktion der Tropoelastin-Synthese bewirken und so zu einer verstärkten Bildung 
Elastin-ähnlicher Fasern durch die senezenten HMEC Populationen beitragen. 
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1 Introduction 
1.1 Cell cycle regulation 
Eukaryotic cellular proliferation, differentiation and development are controlled by the cell cycle. 
This complex mechanism can be divided into distinct phases: the M phase when cell division 
takes place and the interphase between two cell divisions, which is again subdivided in three 
precisely coordinated and regulated sections: G1, S, and G2 phase (Figure 1). Progression of cells 
through the cell division cycle is controlled by an extensive interplay of numerous molecules, 
including cyclin-dependent kinases (CDKs) as key regulatory enzymes (Pines, 1994). The balance 
between CDK activation and inactivation controls whether cells proceed through G1 into S phase 
(G1/S checkpoint), and thus, initiate DNA synthesis, and from G2 to M phase 
(G2/M checkpoint), allowing mitosis (Leake, 1996). Catalytic activation of CDKs requires specific 
dephosphorylation and binding to their regulatory subunit, the appropriate cyclin (Figure 1) 
(Morgan, 1995). Whereas CDKs are consistently expressed throughout the different cell cycle 
phases, cyclin levels are triggered by a precise coordination of synthesis and ubiquitin-dependent 
proteasomal degradation (Pines, 1994; Pagano, 1997). Expression of cyclins is tightly regulated 
and susceptible to a variety of environmental signals and numerous intracellular proteins that 
monitor the progress of events such as DNA replication or mitotic spindle-formation. 
Eventually, the cell decides about cyclin gene transcription in response to these signals (Arellano 
and Moreno, 1997). Binding of the specific cyclin to the appropriate CDK induces 
conformational changes and accessibility of the active center (Jeffrey et al., 1995). However, 
CDK activation additionally requires the phosphorylation of a distinct threonine residue in the 
active site T-loop by CDK-activating kinase (CAK, complex of CDK 7 with cyclin H) (Lolli et 
al., 2004) and the dephosphorylation of a tyrosine and threonine residue in the N-terminal region, 
which is mediated by Cdc25 (cell division cycle 25) dual-specificity phosphatases (Morgan, 1995; 
Nilsson and Hoffmann, 2000).  
Cdc25A is required for progression from G1 to S phase and activates CDK2 in complex with 
cyclin E and cyclin A (Figure 1) (Saha et al., 1997). Cdc25B is primarily activated during S phase 
and is responsible for CDK1/cyclin B dephosphorylation (Nilsson and Hoffmann, 2000). Recent 
studies identified Cdc25A and Cdc25C as additional regulators of CDK1 during G2 phase, and 
thus, confirmed a crucial role for these phosphatases in G2/M transition (Timofeev et al., 2009). 
Upon DNA damage a specific phosphorylation of Cdc25C on serine216 is mediated by CHK1 and 
CHK2 (checkpoint kinase 1 and 2), whereby a binding site for the negative cell cycle regulator 
14-3-3-σ is disclosed (Sanchez et al., 1997; Matsuoka et al., 1998; Yang et al., 2003). Association 
of 14-3-3-σ with Cdc25C thus inhibits its dephosphorylation activity and impedes M phase entry 
(Sanchez et al., 1997). Moreover, hyperphosphorylation of Cdc25A and Cdc25C provokes 
ubiquitinylation and subsequent proteolysis of the Cdc25 phosphatases (Taylor and Stark, 2001; 
Timofeev et al., 2009). 
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Figure 1: A schematic overview of essential steps in cell cycle regulation 
Control of normal cell proliferation involves a multifaceted interplay of an enormous regulation-machinery. After 
mitosis (M phase), the cells can leave the cell cycle in G0 phase for terminal differentiation or a transient cell cycle 
arrest and later re-entry in G1, which is then controlled by CDK3/cyclin C (Ren and Rollins, 2004). Triggered for 
further cell divisions, the cells enter G1 phase, grow and synthesize proteins essential for subsequent DNA-
replication. Crucial effectors required for cell cycle progression are cyclin-dependent kinases (CDKs) in complex 
with their regulatory subunit, the cyclins. The group of D cyclins is predominantly expressed during G1 phase and 
decides about the early cell cycle regulation. At the G1/S checkpoint, cellular signaling determines, whether the cell 
complies with all requirements for later DNA synthesis (during S phase). Formation of the CDK2/cyclin E complex 
and activity of the phosphatase CdC25A allow transition into S phase and cyclin A is expressed to bind CDK2. 
Before mitosis, another restriction point (G2/M checkpoint) controls that all preparations for a successful cell 
division are completed and binding of cyclin B to CDK1 with a simultaneous activation of the appropriate CdC25 
phosphatase eventually facilitates mitosis. In addition, environmental alterations as well as endogenous stimuli can 
interfere with the cell cycle regulation, mediated by CDK-inhibitors (CIP/KIP family and INK4a family). Enhanced 
expression of a CDK-inhibitor and binding to the cyclin-CDK-complex abolishes further cell cycle progression. 
Underlying references are marked in the text. (Cdc25: cell division cycle 25, CDK: cyclin-dependent kinase, CIP: 
CDK-interacting protein, KIP: kinase inhibitor protein, INK4a: polypeptide inhibitors of CDK4 and CDK6) 
 
 
CDK-activation is complemented by specific CDK-inhibitor proteins that underlie stimulation by 
both, factors sensing intrinsic defects (e.g. damaged DNA or insufficient replication) and those 
activated by extrinsic alterations (Figure 2). Binding of distinctive inhibitory proteins to cyclin-
CDK-complexes prevents CDK-activation and triggers a cell cycle arrest. CDK-inhibitors can be 
distinguished into two families: proteins of the CIP/KIP family (including p21Cip1,Sdi1,Waf1, p27, 
p57), which inhibit CDK2, CDK4 and CDK6 (He et al., 2005), and INK4a/ARF family 
members (including p16, P19), which abrogate the activity of CDK4 and CDK6 (Figure 1) 
(Villacanas et al., 2002).  
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These mechanisms and their complex regulation eventually determine cell proliferation and cell 
cycle progression; cell differentiation and an irreversible withdrawal from the cell cycle; 
quiescence and a transient cell cycle arrest; senescence and a permanent cell cycle arrest; or an 
elimination of the cell by apoptosis. 
 
1.2 Cellular senescence 
Somatic cells have a limited proliferative capacity and eventually enter a permanent growth arrest 
state, termed cellular senescence (Hayflick, 1965). However, senescent cells remain in a stable, 
viable and metabolically active form, but acquire a characteristic morphology of enlarged, flat, 
vacuolar cells (Goldstein, 1990). This phenomenon was first described in cultured human 
fibroblasts by Hayflick and colleagues (Hayflick and Moorhead, 1961; Hayflick, 1965). Further 
research has observed cellular senescence in numerous other cell types, such as epithelial or 
endothelial cells, derived from many species (Vojta and Barrett, 1995; Romanov et al., 2001; 
Hughes and Reynolds, 2005; Tsirpanlis, 2008).  
Senescence can be induced by a variety of stimuli such as telomere attrition and DNA damage, 
chromatin perturbations, oxidative stress, oncogene overexpression or persistent signaling by 
anti-proliferative cytokines (Ferbeyre et al., 2002; Narita et al., 2003; Vijayachandra et al., 2003; 
d'Adda di Fagagna, 2008). On the other hand, senescent cells themselves produce high levels of 
reactive oxygen species (ROS), which in turn affect neighboring cells in the microenvironment 
(Song et al., 2005; Bertram and Hass, 2008b). Cellular senescence involves fundamental 
alterations in the regulation of gene expression and is accompanied by an interplay of multiple 
variations in cell signaling mechanisms (Cristofalo et al., 1998; Zhang et al., 2003; Campisi and 
d'Adda di Fagagna, 2007; Bertram and Hass, 2008b), whereof the most essential pathways and 
effectors are subsequently described in more detail. 
 
1.2.1 Telomere-dependent senescence 
Human telomeres comprise tandem repeats of a hexanucleotide sequence (5’-TTAGGG-3’)n of 
approximately 10-15 kilo basepairs (kbp) in length (telomere restriction fragment) that cap and 
stabilize the ends of linear chromosomes to protect the genomic DNA from degradation and 
recombination (Blackburn, 1991; Aviv et al., 2003). Telomeres are synthesized and maintained by 
telomerase, a heterodimeric enzyme with an RNA template subunit (hTERC) and a catalytic 
protein component (hTERT) (Blackburn et al., 1989). A variety of telomere-interacting proteins 
have been identified and mammalian telomeres are thought to end in a large circular structure, 
termed the t-loop (Griffith et al., 1999). 
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Figure 2: Molecular mechanisms involved in the induction of cellular senescence.  
With increasing life span, continuous telomere erosion and finally short telomeres, resembling double stranded DNA 
breaks, induced p53-mediated DNA-damage response with subsequent activation of the CDK-inhibitor p21Cip-1. 
Stress-associated signals, however, utilize activation of the CDK-inhibitor p16INK4a, which in turn causes 
maintenance of hypophosphorylated pRb. Eventually, both the p53/p21Cip1-pathway as well as p16INK4a-mediated 
signaling function as transcriptional regulators and result in cell cycle arrest. Underlying references are marked in the 
text. (53BP1: p53 binding protein 1, ATM: Ataxia telangiectasia mutated, Cdc25: cell division cycle 25, CDK: cyclin-
dependent kinase, CHK1/2: checkpoint kinase 1 and 2, DP: dimerization partner, Ets-1: erythroblastosis twenty six 
oncogene homolog 1, Id1: inhibitor of DNA binding 1, INF-β: interferon-β, MDM2: mouse double minute 2 
homolog, MRE11: meiotic recombination 11, NBS1: Nijmegen breakage syndrome 1, P: phosphorylation, pRb: 
retinoblastoma protein, ROS: reactive oxygen species, TGF-β: transforming growth factor-β) 
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According to the end-replication problem, DNA polymerase is incapable of replicating the very 
ends of DNA. Thus, the telomeres progressively shorten and 50-200 bp are lost with each round 
of replication (Harley et al., 1990). Due to the lack of telomerase activity in normal somatic cells, 
continuous telomere erosion generates critically short telomeres, which lack the t-loop structure 
and resemble DNA after double-strand DNA breaks (DSB). Consequently, dysfunctional 
telomeres stimulate the DNA damage response machinery, which eventually signals the cell to 
cease proliferation (d'Adda di Fagagna et al., 2003; Shay and Wright, 2007). 
The detection of DNA damage foci at sites of the telomeric ends characterizes an accumulation 
of proteins which are typically involved in the classical DNA damage response (e.g. RAD50, 
MRE11, γ-H2AX, ATM, 53BP1, CHK2) (Takai et al., 2003; Herbig et al., 2004) (Figure 2). DSB 
implicate an autophosphorylation of the Ser/Thr kinase ATM, and dissociation from 
homodimeric ATM-complexes relay phosphorylation signals downstream to CHK2, 53BP1 and 
p53 (Figure 2) (Bakkenist and Kastan, 2003). Activated CHK2 is capable of hyper-
phosphorylating Cdc25A, thereby promoting its ubiquitylation and subsequent degradation, 
resulting in inefficient activation of CDKs and cell cycle arrest (cp. 1.1) (Busino et al., 2004). 
Likewise, Cdc25C, which is required for the activation of CDK1/cyclin B to enter mitosis, is 
inactivated by CHK1 and CHK2 kinase activity (Sanchez et al., 1997; Chaturvedi et al., 1999). 
Phosphorylation of the tumor suppressor protein p53 is followed by the release of its repressor 
MDM2 and subsequent p53 activation (Datta and Nicot, 2008). p53 subsequently activates the 
expression of several genes, including the one encoding for the CDK-inhibitor p21Cip1 (Jackson 
and Pereira-Smith, 2006). p21Cip1 impedes binding of CDK2 and CDK4 with their regulatory 
subunits cyclin E and cyclin A, respectively, and thus, inhibits CDK activity (Figure 2). However, 
this kinase activity is necessary for the activation of proteins required for the G1/S transition, and 
consequently, the p53-mediated DNA damage response via p21Cip1 induces a G1 arrest in the cells 
(Harper et al., 1993).  
Besides a direct activation of transcription factors, CDK2 and CDK4 regulate phosphorylation of 
the retinoblastoma protein (pRb). Governed by its phosphorylation state, pRb binds to and 
interacts with a variety of proteins and thereby modulates the activity of many transcription 
factors (Tamrakar et al., 2000). Thus, phosphorylation of pRb entails its inactivation and 
subsequent release of the transcription factor complex E2F/DP (Figure 2) (Connell-Crowley et 
al., 1997). Accordingly, free E2F/DP complexes ensure activation of genes necessary for DNA 
synthesis and cell cycle progression (Maiti et al., 2005). In contrast, hypophosphorylated, active 
pRb forms a tight complex with E2F/DP and thereby inhibits the G1 to S phase transition 
(Figure 2) (Cooper et al., 1999).  
The signaling mechanisms that determine whether p21Cip1 provokes a transient growth arrest 
during the classical DNA damage response or a permanent withdrawal from the cell cycle 
associated with cellular senescence are still unknown. 
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1.2.2 The p16INK4a-mediated senescence  
A permanent cell cycle arrest and the induction of senescence can also be stimulated by the 
CDK-inhibitor p16INK4a. Presence of p16INK4a inhibits the formation of complexes between D-
type cyclins and CDK4 or CDK6, respectively, and likewise maintains the hypophosphorylated 
form of pRb, inhibiting the S phase entry (Figure 2) (Hara et al., 1996). However, the stimuli and 
the intracellular system that cause p16INK4a induction are poorly understood. Unlike p21Cip1, 
p16INK4a activation is not directly related to DNA damage-induced senescence by telomere 
shortening (Herbig et al., 2004). Typically, the p16INK4a-pathway is initiated by delayed kinetics 
when compared to p53-mediated DNA damage response, and thus, serves as a secondary 
mechanism to prevent cellular growth upon telomeric dysfunction (Jacobs and de Lange, 2005). 
Conversely, in the context of a premature stress-induced senescence there are stimuli such as 
oxidative stress and oncogene expression that primarily act through p16INK4a induction (Palmero 
and Serrano, 2001; Serrano and Blasco, 2001; Jacobs and de Lange, 2004). A potential molecular 
mechanism of p16INKa4 activation is controlled by Id1, a transcriptional repressor of p16INK4a. In 
senescent cells, Id1 expression is down-regulated and thus expression of the p16INK4a cell cycle 
inhibitor is enhanced (Alani et al., 2001). In contrast, it could be demonstrated that the 
transcription factor Ets-1 accumulates in senescent cells and functions as an activator of p16INK4a 
(Ohtani et al., 2001). Recently, binding experiments revealed the homeodomain protein Meox2 as 
an additional transcriptional activator of p16INK4a in association with the induction of premature 
senescence (Irelan et al., 2009). However, the detailed signaling pathways that contribute to the 
senescence-associated activation of p16INK4a still remain vague. Moreover, susceptibility to the 
CDK-inhibitor p16INK4a is largely cell type-dependent, and e.g. human mammary epithelial cells 
(HMEC) are more prone to the induction of a cell cycle arrest by p16INK4a than human fibroblasts 
(Stein et al., 1999; Romanov et al., 2001). 
 
1.2.3 Cellular senescence in human mammary epithelial cells (HMEC) 
Depending on the tissue and species of origin, cells underlying cellular senescence may differ in 
both their typical senescent phenotype and the importance of certain signaling pathways for the 
senescence response. Distinctive aspects characteristic for the process of cellular senescence in 
human mammary epithelial cells (HMEC) will be explained. Several stimuli and mechanisms are 
known to be involved in the prevention of infinite growth and an induction of senescence in 
HMEC (Shelton et al., 1999; Sandhu et al., 2000; Yaswen and Stampfer, 2002; Zhang et al., 2003). 
One early mechanism is associated with a dramatic increase in p16INK4a and is mediated by the 
pRb tumor suppressor protein, causing first a stress-associated senescence barrier, termed stasis 
(stress or aberrant signaling-inducing senescence) (Figure 3) (Yaswen and Stampfer, 2002; Narita 
et al., 2003). Accordingly, HMEC viably arrest in the G1 cell cycle phase and reveal a reduced 
telomere restriction fragment length of about 6-8 kbp (cp. 1.2.1). Moreover, activity of the 
enzyme senescence-associated β-galactosidase (SA β-gal) is significantly enhanced in senescent 
HMEC (Dimri et al., 1995; Romanov et al., 2001).  
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SA β-gal was originally described as an aging biomarker by Dimri and colleagues in 1995 (Dimri 
et al., 1995). Per definition, this enzyme activity is histochemically detectable at pH 6 and should 
distinguish senescent cells from quiescent or terminally differentiated cells (Dimri et al., 1995). 
However, its function during cellular senescence and the suitability and validity of this enzyme 
activity in the context of senescence is controversial. Positive SA β-gal cells could also be 
detected upon inadequate culture conditions, serum starvation, cell confluence, H2O2 treatment 
and genetic manipulations (Severino et al., 2000; Yang and Hu, 2005; Lee et al., 2006). Thus, 
SA β-gal cannot be considered as a universal marker of senescence, and at most, is utilized in 
combination with the verification of other senescence-associated alterations such as cell cycle 
distribution, expression of p21Cip-1 or p16INK4a.  
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Figure 3: Cellular senescence in HMEC. 
A dramatic increase in expression of the CDK-inhibitor p16INK4a in HMEC induces a state of stress-associated 
premature senescence, termed stasis. Some growth-arrested cells, however, underlie gene silencing of p16INK4a by 
post-translational hypermethylation of the p16 promoter and regain proliferative capacity. Continuous telomere 
erosion stimulates the DNA damage response and HMEC encounter a second growth arrest, termed agonescence. 
Further proliferation of agonescent HMEC due to inactivation of p53 entails a crisis-like state with extensive cell 
death. However, simultaneous reactivation of the enzyme telomerase in agonescent cells is associated with malignant 
cell transformation and potential tumor development. Underlying references are marked in the text. 
 
Remarkably, some of these stasis-arrested HMEC are subjected to a self-selection process 
triggered by hypermethylation of the p16 promoter and subsequent loss of p16INK4a expression 
(Brenner et al., 1998; Huschtscha et al., 1998). Due to an improper G1 checkpoint control, these 
post-selection HMEC escape from the growth plateau and resume proliferative capacity. 
However, the lack of telomerase activity in somatic cells causes continuous telomere erosion, 
eventually generating critically short telomeres and prevalent chromosomal aberrations (Harley et 
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al., 1990; Shay and Wright, 2007). The subsequent initiation of the DNA damage response (cp. 
1.2.1) causes a withdrawal from the cell cycle and the post-selection HMEC encounter a second 
senescence barrier which is telomere length-dependent and termed agonescence (Figure 3) 
(Yaswen and Stampfer, 2002). The agonescent cells remain viable and metabolically active, but 
acquire characteristic morphological and functional changes of a senescent phenotype. They 
display a dramatic decrease in the mean telomeric length (about 4-5 kbp) and typically arrest in 
the G1 and G2 cell cycle phases, but retain long-term viability (Romanov et al., 2001; Tlsty et al., 
2001). Inactivation of the tumor suppressor protein p53 and impaired cell cycle checkpoints in 
agonescent HMEC can partially restore cell divisions, which in combination with the telomeric 
dysfunctions induce massive cell death, a process termed crisis (Figure 3) (Garbe et al., 2007; 
Hornsby, 2007). Elimination of dying HMEC can be performed following internalization by 
neighboring cells, termed entosis (Overholtzer et al., 2007). In contrast, escape from these 
processes by reactivation of the telomerase activity in senescent post-selection HMEC can 
contribute to a malignant cell transformation, and thus, a potential breast cancer development 
(Kirkpatrick et al., 2003; Herbert et al., 2007). 
 
1.2.4 Cellular senescence in relation to organismal aging 
It has been hypothesized that cellular senescence, extensively investigated and defined using in 
vitro cell culture models, may reflect cellular aging in vivo and might contribute to the physiological 
processes of normal organismal aging (d'Adda di Fagagna, 2008; Jeyapalan and Sedivy, 2008). But 
the relationship between mechanisms inducing senescence and those that trigger aging of a 
multifaceted organism remains to be established. Whereas cellular senescence cannot be 
explained by a single distinct mechanism, but is rather an elaborated interaction of numerous 
signal transduction pathways, the complexity of organismal aging is additionally determined by 
intercellular processes and the interplay of the tissue system. Some of the senescence-associated 
alteration mentioned above could be observed to accumulate with age in vivo, but it has to be 
considered that none of these signals could be proven to be exclusively restricted to senescence in 
vitro. For example, in a variety of mammalian tissues such as skin, liver, ovary and uterus 
expression of the CDK-inhibitor p16INK4a and its transcriptional activator Ets-1 simultaneously 
increased with advancing age (Krishnamurthy et al., 2004; Jeyapalan et al., 2007). Normal breast 
epithelial cells displayed hypermethylation of the p16 promoter in vivo similarly to the post-
selection process described for HMEC in vitro (Holst et al., 2003). In skin biopsies derived from 
aged baboons an accumulation of dermal fibroblasts was detected exhibiting cellular senescence-
associated changes such as dysfunctional telomeres, enhanced ATM activation, elevated levels of 
proteins related to chromatin perturbations as well as increased expression of p16INK4a (Jeyapalan 
et al., 2007). An enrichment of senescent cells in the aging organism may reach a point that 
compromises the normal functionality of a particular tissue and may contribute to the 
development of age-associated diseases such as atherosclerosis, Alzheimer’s or cardiovascular 
disease (Flanary et al., 2007; Golubnitschaja, 2007; Andreassi, 2008). 
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Data resulting from investigations based on in vitro cell culture systems might not entirely reflect 
the complex processes in vivo, but could partially provide new insights into organismal aging and 
might help in understanding the complex interplay of human aging and age-related disease.  
 
1.2.5 The two faces of cellular senescence: tumor suppression and cancer-promotion 
The growth inhibitory capacity of cellular senescence is accomplished by activation of the tumor 
suppressor proteins p53 and pRb, respectively, and subsequent induction of a permanent cell 
cycle arrest (cp. 1.2.1 and 1.2.2).  
Besides the repression of cell cycle progression genes, senescent cells exhibit a marked up-
regulation of genes encoding for secretion proteins (secretome) such as cytokines, growth factors 
and matrix-degrading enzymes (Millis et al., 1992; Shelton et al., 1999; Coppe et al., 2006). All 
these signaling molecules and enzymes confer an important function during embryonic 
development as well as in repair mechanisms such as wound healing in the adult organism. 
However, contemporary with an accumulation of senescent cells in the aging tissue, a deregulated 
senescence-associated secretome can significantly affect surrounding cells and may provoke 
severe consequences, including pathological developments and tumor growth (Krtolica et al., 
2001; Parrinello et al., 2005; Liu and Hornsby, 2007). Thus, an increase in secreted growth factors 
may stimulate susceptible adjacent cells to proliferate, whereby inflammatory cytokines can 
induce local oxidative stress. Whereas the vascular endothelial growth factor (VEGF) is necessary 
for embryonic neovascularization, an enhanced expression of VEGF by senescent fibroblasts was 
also shown to promote tumor vascularization and to support higher proliferation of malignant 
cells in mice (Coppe et al., 2006). Activation of certain matrix metalloproteinases (MMPs) 
initiates extracellular remodeling and facilitates cell migration during wound healing (Kyriakides 
et al., 2009), but also improves the motility of tumor cells and contributes to metastatic 
development (Liu and Hornsby, 2007). In addition, MMP-induced alterations of the tissue 
environment such as extracellular matrix disruption or an increased capillary permeability 
implicate an enlarged release of active mitogens, cytokines and other plasma products (cp. 
1.3.3.4) (Millis et al., 1992; Liu and Hornsby, 2007). The continuous exposure to a high 
concentration of growth promoting factors may reactivate proliferation of susceptible damaged 
cells and eventually favors a malignant transformation. On the other hand, matrix compounds 
such as laminin also directly affect activation of distinct precursor proteins and trigger 
intracellular signal transduction mechanisms whose deregulation supports proliferation and 
tumorigenicity of neighboring premalignant and malignant cells (Kang et al., 2008; Sprenger et al., 
2008).  
Early in life cellular senescence acts as a control system to prevent proliferation of damaged cells 
and represents an important tumor suppressive mechanism (Hornsby, 2007). However, altered 
gene expression and impaired function of senescent cells together with their continuous 
accumulation with increasing organismal age contribute to deleterious changes of the cell, 
eventually culminating in age-related disease and tumorigenic developments. These investigations 
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substantiate the theory of senescence as an antagonistic pleiotropic phenomenon, already 
hypothesized by Williams in 1957, claiming the existence of genes to be beneficial in young 
organisms but adopting harmful functions later in life (Williams, 1957). 
 
1.3 The extracellular matrix (ECM) 
The extracellular microenvironment is accredited with an increasing and influentially importance 
for physiological processes as well as pathological developments and tumorigenesis (Marastoni et 
al., 2008; Mbeunkui and Johann, 2009). The ECM represents an interacting network of 
scaffolding proteins, adhesive glycoproteins and proteoglycans that provide structural and 
mechanical support to cells and tissues. Moreover, as a storage system for numerous growth 
factors, chemokines and cytokines, the ECM holds an important function related to the 
activation and distribution of these signaling molecules (Taipale and Keski-Oja, 1997; Schonherr 
and Hausser, 2000). Thus, alterations in the composition and structure of the scaffolding matrix, 
disordered release of soluble signaling molecules, modified expression of proteoglycans and cell 
adhesion molecules or abnormal cell-matrix interactions play a crucial role for a variety of cellular 
signaling mechanisms, eventually deciding about proliferation, gene expression, differentiation or 
cell death and adhesion, migration or invasion, respectively (Pupa et al., 2002; Larsen et al., 2006; 
Huveneers et al., 2007; Kunz, 2007; Ghajar and Bissell, 2008). 
 
1.3.1 The extracellular structural filament 
The scaffolding fibers such as collagen and elastin provide biomechanical strength, shape and 
flexibility to the tissue (Ottani et al., 2001). This is supported by structural glycoproteins (e.g. 
fibronectin, laminin and vitronectin) and proteoglycans, which additionally provide an essential 
connective link between ECM and adjacent cells (Farhadian et al., 1995).  
1.3.1.1 Collagen fibers and structural glycoproteins 
Glycoproteins can adhere to the collagen and elastin scaffold and stabilize the extracellular 
network (Farhadian et al., 1995). On the other hand, these ECM proteins are able to interact with 
certain cell surface receptors, of which integrins constitute the most typical class, and play a 
crucial role in cell-matrix communication (Zhu et al., 1998). Hence, structural glycoproteins such 
as fibronectin or laminin ensure attachment of adjacent cells to the ECM and relate extracellular 
alterations to cellular signal transduction pathways and intracellular responses (Bosman and 
Stamenkovic, 2003). Fibronectin and other glycoproteins of this family present an essential 
binding factor for various secreted proteins, including collagen, tropoelastin, fibrillins and lysyl 
oxidases, and assist further processing and maturation on the cell surface (Fogelgren et al., 2005; 
Hinek et al., 2006; Kadler et al., 2008; Sabatier et al., 2009). The ability of fibronectin to bind 
both cell surface integrins and collagen represents an essential part of collagen fibril formation in 
vivo, however, the detailed mechanisms are still unknown (Kadler et al., 2008). More than 20 
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genetically distinct collagen molecules are known, but the most abundant are collagen I and II 
that are arranged in fibrils (also III, V, XI)  (Kadler et al., 1996). Other collagens are associated 
with these fibrils (VI, IX, XII, XIV), form networks (IV, VIII, X) or repetitive beaded structures 
(VI) or represent transmembrane proteins (XIII, XVIII) (Bosman and Stamenkovic, 2003). 
Collagen is synthesized as precursor protein pro-collagen which undergoes extensive post-
translational modifications requiring distinct chaperones and enzymes that assist folding and 
trimerization (Lamande and Bateman, 1999). Thus, conversion of proline residues in 
hydroxyproline by prolyl-4-hydroxylase is necessary for collagen packaging and the chaperone 
HSP47 carries an essential role for collagen folding and control of its aggregation (Smith et al., 
1995; Myllyharju, 2003). Processing of pro-collagen, a key step during collagen fibril formation is 
mediated by two families of metalloproteinases. The N-terminus is truncated by ADAMTS (a 
desintegrin and metalloproteinase with thrombospondin motif) and the C-terminal pro-peptide is 
cleaved by members of the tolloid family of zinc metalloproteinases (e.g. bone morphogenetic 
protein-1 (BMP-1)) (Kessler et al., 1996; Fernandes et al., 2001). In vitro collagen fibril formation 
can occur in a self-assembly process, however, recent data verified that fibrillogenesis in vivo is 
dependent on the presence of fibronectin and fibronectin/collagen-binding integrins as well as 
collagen V as nucleator (Kadler et al., 2008). Maturation to strong, resistant collagen fibers, 
consisting of multiple fibrils, is strengthened by networking with small proteoglycans and 
formation of additional intra- and intermolecular cross-links by lysyl oxidases (Eyre et al., 1984; 
Danielson et al., 1997). Whereas the involvement of the lysyl oxidase LOX in the oxidation of 
mature collagen I fibrils was demonstrated (Siegel, 1974), the role of other LOX-like (LOXL) 
isoforms is rather tissue-specific and varies depending on the collagen type (Lucero and Kagan, 
2006). 
1.3.1.2 Elastic fiber formation and microfibrils 
Whereas the processes, which contribute to the formation of collagen fibers, are widely clarified, 
little is known about the precise mechanisms of elastic fiber assembly. These fibers are the largest 
structure in the ECM and are comprised of two major compounds, an inner amorphous elastin 
core and an outer scaffold of microfibrils, endowing tissues such as lung, blood vessels, tendon 
and skin with the critical properties of elastic recoil and resilience (Mithieux and Weiss, 2005). 
Elastin is a highly stable, enzymatically resistant, hydrophobic polymer composed of cross-linked 
molecules of its precursor protein tropoelastin (Wagenseil and Mecham, 2007).  
The tropoelastin protein demonstrates a characteristic alternating pattern of hydrophobic and 
hydrophilic, lysine-containing domains (Gray et al., 1973). These functional distinct elements are 
encoded in separate exons on the tropoelastin gene (Rosenbloom et al., 1995). However, the 
generated mRNAs are highly variable and about eleven protein isoforms in the range of 60-
72 kDa are known that arise from multiple alternative splicing of the primary transcript (Wise and 
Weiss, 2009). The pattern and frequency of exon splicing is precisely regulated during 
development (Parks et al., 1988), but the specific conditions deciding about expression of 
individual isoforms are not known. Conversely, the C-terminal region is highly preserved. It 
Introduction 
 
12 
 
delineates cell- and ECM-interacting sites and is supposed to play a crucial role in assembly and 
cross-linking of the tropoelastin monomers (Broekelmann et al., 2008). The protein sequence is 
dominated by the hydrophobic amino acids valine, alanine, proline and glycine, generating the 
characteristic repetitive VGVAPG-hexapeptide (Price et al., 1993). Tropoelastin undergoes no 
post-translational modifications such as glycosylation, but due to the substantial amount of 
proline residues, the peptidyl-prolyl cis-trans isomerase FKBP65 confers the protein with essential 
restructuring (Davis et al., 1998; Patterson et al., 2005) (Figure 4). Additional folding is facilitated 
by interaction with the HSP70 molecular chaperone BiP in the endoplasmic reticulum (ER) 
(Davis et al., 1998). The tropoelastin protein follows the classical protein secretion pathway, 
traversing the Golgi apparatus and being packed into secretory vesicles (Davis and Mecham, 
1998). Tropoelastin trafficking is supported by the elastin binding protein (EBP), which acts as 
recyclable chaperone and assists secretion of tropoelastin (Hinek et al., 1995). This process 
requires complex binding of EBP with the enzyme neuraminidase-1 (Neu-1) and protective 
protein/cathepsin A (PP) (Figure 4). Neu-1 activity ensures interaction of EBP with extracellular 
glycoproteins, which in turn induces release of tropoelastin at the cell surface (Hinek et al., 2006). 
Recent studies revealed Neu-1 to be essential for deposition of several other elastic fiber-
associated proteins (e.g. fibrillin-2 and fibulin-5), and thus, represents a crucial factor involved in 
elastic fiber assembly (Starcher et al., 2008). Secreted tropoelastin is tethered to the cell surface, 
where it aggregates into small organized spheres and is bound by scaffolding microfibrils (Figure 
4) (Kozel et al., 2006). The interaction with microfibrillar proteins is crucial for deposition and 
alignment of tropoelastin, which is required for the next phase of elastogenesis, the so-called 
coacervation (Broekelmann et al., 2005; Kozel et al., 2006). Multiple tropoelastin molecules grow 
into larger structures (Figure 4) dedicated by the precise patterning of mostly alternating 
hydrophobic and hydrophilic sequences in the protein (Toonkool et al., 2001; Wagenseil and 
Mecham, 2007). This characteristic organization is thought to be required for subsequent 
intermolecular cross-linking and eventual incorporation into growing elastic fibers (Mithieux and 
Weiss, 2005; Wagenseil and Mecham, 2007).  
Microfibrils form the outer sheath of the mature elastic fiber and play a crucial role in 
elastogenesis, providing scaffold sites for depositing tropoelastin (Cleary and Gibson, 1983; 
Sherratt et al., 2001). Microfibrils are small structures composed of several glycoproteins, 
including fibrillins and MAGPs (microfibril-associated glycoproteins) (Kielty et al., 2005). 
Fibrillin-1 and fibrillin-2 are the principal elements of microfibrils and represent large cysteine-
rich glycoproteins (~350 kDa), whose primary structure is dominated by multiple repeated 
domains homologous to the Ca2+-binding epidermal growth factor (cbEGF) module (Handford 
et al., 2000). Ca2+-binding stabilizes contiguous cbEGF regions into a beaded rod-like structure, 
and thus, favors proper assembly of microfibrils (Downing et al., 1996; Wess et al., 1998). In 
addition, fibrillins possess several domains crucial for their interaction with distinct binding 
partners (Figure 5). Thus, heparin-binding domains contribute to proteoglycan (PG) interaction 
and Arg-Gly-Asp (RGD) sequences are related to cell surface integrin-binding, both imparting 
microfibrillar assembly (Tiedemann et al., 2001; Bax et al., 2003; Ritty et al., 2003). A TGF-β-
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binding (TB) module confers fibrillins with an essential role in growth factor presentation and 
sequestering, and improper regulation causes severe pathological developments (e.g. Marfan 
syndrome) (Neptune et al., 2003). Furthermore, fibrillin-1 and fibrillin-2 bind to tropoelastin, 
confirming their function in elastic fiber maturation (Figure 4) (Trask et al., 2000).  
Several other microfibril-associated proteins have been identified, including MAGPs (matrix-
associated glycoproteins), fibulins and EMILINs (elastin-microfibril-interface located proteins) 
(Bressan et al., 1993; Henderson et al., 1996; Timpl et al., 2003). However, their distinct 
contribution to microfibrillar and elastic fiber assembly still remains vague. MAGPs are small 
glycoproteins of about 20 kDa that localize to the beaded structure of microfibrils (Henderson et 
al., 1996). MAGP-1 interacts with both fibrillin-1 as well as tropoelastin and is supposed to act as 
a bridge molecule in elastic fiber maturation (Figure 4 and Figure 5) (Brown-Augsburger et al., 
1996; Jensen et al., 2001). MAGP-2 is a serine- and threonine-rich protein and contains RGD-
sequences mediating integrin-binding (Gibson et al., 1999), and thus, may function in cellular 
signal transduction during microfibril assembly and elastogenesis. EMILIN-1 (~106 kDa) 
belongs to a family of glycoproteins which can associate with elastic fibers (Bressan et al., 1993). 
It binds tropoelastin as well as fibulin-5, but is also involved in cell attachment via interference 
with certain integrins and may entail both elastic fiber integrity as well as distinct cell-ECM 
adhesion properties (Figure 5) (Spessotto et al., 2003; Zanetti et al., 2004). Five members of the 
fibulin family are known so far (Timpl et al., 2003). They represent a structure dominated by a 
series of cbEGF domains and demonstrate different abilities to bind tropoelastin, fibrillin-1, 
fibronectin and PGs (Figure 5) (Timpl et al., 2003). Fibulin-1 (~77 kDa) associates with the 
elastin core but not with microfibrils (El-Hallous et al., 2007), whereas fibulin-2 (~127 kDa) 
strongly binds to tropoelastin and to fibrillin-1 in a Ca2+-dependent manner (Reinhardt et al., 
1996). Fibulin-2, fibulin-5 (~50 kDa) and to a less extent fibulin-4 (~50 kDa) are critical 
components for elastic fiber formation. As they provide binding sites for both tropoelastin as 
well as fibrillin-1, they may function as molecular bridge between microfibrils and elastin (Figure 
4) (El-Hallous et al., 2007). Recent studies specified the function of fibulin-5 in elastin fiber 
assembly and demonstrated its requirement for activation of pro-lysyl oxidase-like-1 (proLOXL1) 
as well as elastin incorporation into the microfibrils (Choi et al., 2009). In addition, fibulin-5 
interacts with cell surface integrins via its RGD motif, and thus, may anchor elastic fibers to the 
cells (Yanagisawa et al., 2002; Nonaka et al., 2009). 
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Figure 4: Formation of microfibrils and maturation of elastic fibers 
A detailed description of the mechanism is given in the text. (BiP: heat shock 70kDa protein 5, E-1: EMILIN-1: 
elastin-microfibril-interface located protein-1, EBP: elastin binding protein, Fib-1: fibrillin-1, FKBP65: FK506 
binding protein, FN: fibulin, HSPG: heparan sulfate proteoglycan, LOX: lysyl oxidase, LOXL1: lysyl oxidase-like 1, 
M-1: MAGP: matrix-associated glycoprotein-1, Neu-1: neuraminidase-1, PP: protective protein/cathepsin A) 
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The detailed mechanisms involved in the intracellular trafficking of proteins required for the 
formations of microfibrils are not yet understood. Fibrillins that form the major backbone of 
microfibrils interact in the ER with several chaperones e.g. calreticulin, facilitating folding and 
post-translational modifications such as N-glycosylation (Ashworth et al., 1999). Traversing the 
constitutive secretory pathway, fibrillin-1 undergoes initial assembly to form dimers and 
multimers and subsequent extracellular deposition requires cleavage of the C-terminal end by the 
serine protease furin convertase (Ritty et al., 1999). Microfibrils assemble close to the cell surface 
and recently, binding experiments revealed important interactions of fibrillins with the 
glycoprotein fibronectin (Sabatier et al., 2009). Moreover, latest studies substantiated that binding 
of fibrillins to cell surface integrins via their RGD domain as well as interactions with heparan 
sulfate PGs support fibrillogenesis (Tiedemann et al., 2001; Tsuruga et al., 2009). Maturation of 
microfibrils is associated with conformational changes and transglutaminase-catalyzed cross-links 
between fibrillin molecules as well as with MAGPs, which impart main stability to the 
microfibrils (Mecham et al., 1995; Qian and Glanville, 1997; Trask et al., 2001). Moreover, 
transglutaminase-dependent cross-linking of fibrillin-1 with tropoelastin molecules assists their 
deposition on the microfibrils and establishes eventual maturation of the complex elastic fiber 
(Rock et al., 2004). 
 
 
 
 
Figure 5: Protein interactions during elastic fiber maturation 
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1.3.1.3 Lysyl oxidases (LOs) 
The family of lysyl oxidases includes at least five members, LOX and 4 LOX-like (LOXL) 
enzymes (Csiszar, 2001), whereof particularly LOX and LOXL1 are recognized as essential 
catalytic enzymes for oxidative cross-linking of lysine residues of the extracellular fiber proteins 
collagen and elastin, accounting for insolubilization and stabilization of the ECM (Smith-Mungo 
and Kagan, 1998; Wagenseil and Mecham, 2007). LOX and LOXL1 are most similar to each 
other, whereas LOXL2, LOXL3 and LOXL4 seem to build a second subfamily (Lucero and 
Kagan, 2006). LOs are secreted as N-glycosylated pro-enzymes, which enclose a N-terminal 
signal peptide followed by a variable region and a highly conserved C-terminus (Csiszar, 2001). 
Prior to activation, the secreted pro-enzyme is required to associate with the structural 
glycoprotein fibronectin on the extracellular cell surface (Fogelgren et al., 2005) and can then be 
cleaved by pro-collagen C-proteinase (BMP-1), resulting in loss of the glycosylated pro-peptide 
(Cronshaw et al., 1995; Panchenko et al., 1996). In addition, the activity of this redox enzyme 
family is dependent on two essential cofactors, a Cu2+ and a covalently bound lysyl tyrosine 
quinone (LTQ) (Figure 6a) (Wang et al., 1996).  
The detailed mechanism involved in the oxidation of lysine residues in LO substrates that 
eventually permits intra- and intermolecular cross-links is shown in Figure 6b. It is suggested that 
in an intracellular self-processing reaction, Cu2+ initially catalyzes the oxidation of a specific 
tyrosine residue, resulting in a peptidyl dihydroxyphenylalanine quinone, which covalently binds 
to an adjoining lysyl ε-amino group. Final oxidation and transfer of the electrons to molecular 
oxygen generates the LTQ-cofactor as a transient electron sink (Figure 6a) (Bollinger et al., 2005). 
In the first step of the catalytic LO mechanism, one LTQ-carbonyl group reacts with the lysyl ε-
amino group of the substrate, creating a Schiff base (1). A base-facilitated abstraction of the lysyl 
α-proton forms a reduced lysyl-tyrosyl-aminoquinol (2). Following hydrolysis of this imine 
intermediate, the release of the aldehyde product and the reduced LTQ is induced (3). 
Reoxidation of the cofactor is mediated by transferring two electrons on molecular oxygen 
producing hydrogen peroxide (4). Finally, the quinoneimine is hydrolyzed, resulting in 
regeneration of the original LTQ-cofactor and release of free ammonia (5) (Williamson and 
Kagan, 1986, 1987). The produced aldehyde then spontaneously interacts with unmodified lysyl 
ε-amino groups or with other aldehyde groups generating intra- and interpeptide chain cross-links 
(Lucero and Kagan, 2006). Spontaneous cross-linking of oxidized tropoelastin and elastin 
molecules results in the characteristic formation of the amino acid desmosine (Mecham et al., 
1995). The production of hydrogen peroxide during this enzymatic reaction facilitates LOs 
activity measurements in vitro (Trackman et al., 1981).  
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Figure 6: LO catalytic mechanism. 
(a) LO activity is dependent on Cu2+ which catalyses the reaction of the ε-amino group of a lysine residue with an 
adjacent tyrosine residue generating the lysyl tyrosine quinone (LTQ)-cofactor. A detailed description is given in the 
text. (b) The enzymatic mechanism facilitating cross-links between lysine residues of tropoelastin molecules and 
matured collagen fibrils involves the carbonyl-groups of the LTQ-cofactor. Initially, one carbonyl-group reacts with 
the lysyl ε-amino group of the substrate (1). The essential basic environment (B) for this reaction mediates 
abstraction of the lysyl α-proton resulting in a reduced lysyl-tyrosyl-aminoquinol (2). Hydrolysis induces the release 
of the aldehyde product and a reduced LTQ-cofactor (3). Transfer of two electrons on molecular oxygen (4) and 
subsequent hydrolyzation of the quinoneimine (5) regenerates the original LTQ-cofactor under release of hydrogen 
peroxide and ammonia (4 and 5). The scheme is adapted from (Lucero and Kagan, 2006). 
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The electrostatic potential between the LO enzyme and its substrate plays an essential role in 
substrate specificity (Kagan et al., 1984). The particular preference of LOX and LOXL1 for 
cationic substrates might be explained by the LTQ-containing active site, which is surrounded by 
anionic amino acids (Lucero and Kagan, 2006). This is supported by the fact that LOX and 
LOXL1 are able to directly react with the elastin precursor tropoelastin, which possesses the 
appropriate electrostatic feature next to lysine residues, whereas oxidation of collagen does not 
happen before the generation of mature collagen fibers, possibly creating a more favorable 
environment (Gray et al., 1973; Lucero and Kagan, 2006). 
Functionality of LO enzymes is of prime importance for the organism, demonstrated by 
numerous diseases associated with disordered LO activity such as lethal aortic aneurisms, 
dysfunction of the pulmonary system or skin disorders (Maki et al., 2005; Szauter et al., 2005; 
Rodriguez et al., 2008). Besides their extracellular activity, LOX and LOXL1 were detected in the 
cell nuclei (Nellaiappan et al., 2000) and might be involved in the modification of certain 
histones, implicating chromatin remodeling and altered transcriptional regulation (Giampuzzi et 
al., 2003). However, the detailed mechanisms involved in enzyme translocation and the precise 
function of nuclear LO are still obscure.  
 
1.3.2 Proteoglycans (PGs) 
Proteoglycans (PG) exist in the ECM, cell-associated and intracellular in secretory granules 
(Bajorath et al., 1998; Henningsson et al., 2006). These molecules are characteristically composed 
of a core protein and one or more covalently bound linear carbohydrate polymers, the 
glycosaminoglycans, consisting of repetitive, specifically sulfated disaccharides (Yanagishita et al., 
2008). PGs appear as integral proteins or as extracellular cell surface proteins, covalently linked to 
glycosylphosphatidylinositol (GPI) anchors at the cell membrane (Ponta et al., 1998; Matsuda et 
al., 2001). Interference with a variety of factors is mediated either by charge interaction via the 
glycosaminoglycan chains or by specific domains within the core protein (Wight et al., 1992). 
PGs are involved in cell-cell adhesion as well as cell-matrix anchorage, and play a pivotal role in 
growth factor presentation and the induction of associated signaling pathways. However, the 
expression of particular PGs differs with cell type and tissue origin (Lories et al., 1992). As an 
extracellular reservoir for signaling molecules, PGs influence activation, localization and 
accessibility of growth factors and cytokines, which emphasizes the importance of these ECM 
compounds in the maintenance of regulated signal transduction (Bernfield et al., 1992; Ponta et 
al., 1998; Kresse and Schonherr, 2001). Thus, impaired expression levels or atypical post-
translational modifications of PGs cause altered responses to mitogenic signals, involving 
influences of the cell homeostasis and growth, eventually favoring pathological and malignant 
transformations (Matsuda et al., 2001; Liu et al., 2003a). Previous work revealed down-regulated 
levels of syndecan-1 in various cancers and suppression of this heparan sulfate PG (HSPG) was 
associated with epithelial cell transformation and mammary tumor development (Lundin et al., 
2005; Choi et al., 2007; Su et al., 2007). In contrast, glypican-1, which represents an essential 
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factor in heparin-binding growth factor-mediated signaling, demonstrated low levels in normal 
breast tissue, but was highly overexpressed in breast cancers, thus, rendering malignant cells more 
sensitive to mitogenic signals (Matsuda et al., 2001). As a major binding partner and effector of 
hyaluronic acid, the HSPG CD44 imparts extracellular alteration of hyaluronan to intracellular 
signaling mechanisms, thereby stimulating cell proliferation, differentiation and migration (Heldin 
et al., 2008). One possible mechanism is demonstrated by hyaluronan/CD44-mediated 
transactivation of downstream signals via ErbB1 involving the protein kinase C (PKC) family and 
Rac1. This causes activation of proteins involved in cytoskeleton reorganization and secretion of 
MMP-2, which eventually promotes cell migration (Kim et al., 2008). On the other hand, 
ectodomain shedding of CD44 by the transmembrane MT1-MMP (membrane type I matrix 
metalloproteinase) provokes the release of a soluble CD44-fragment which has also a cell 
motility-stimulating effect (Kajita et al., 2001). Furthermore, CD44 bears a crucial role in cytokine 
and growth factor presentation and the cell-specific presence of distinct CD44 variants enables 
specialized cellular functions (Mackay et al., 1994; Naor et al., 1997). The isoform CD44v3 
(variant 3) is involved in extracellular presentation of the heparin-binding epidermal growth 
factor-like growth factor (HB-EGF). In addition, it binds the matrix metalloproteinase-7 (MMP-
7) which subsequently facilitates proteolytic activation of HB-EGF. The ability of CD44v3 to 
simultaneously recruit the ErbB4 and ErbB1 receptor, respectively, ensures immediate signal 
transduction (Yu et al., 2002). The isoforms CD44v6 and CD44v9 were shown to interact with 
the Fas death receptor and thereby inhibit Fas-mediated signaling, which confers the cells with an 
important anti-apoptotic mechanism (Mielgo et al., 2006).  
Impaired PG expression, structure and function, induced by transcriptional or post-translational 
alterations, may affect various intracellular signaling mechanisms and cellular adhesion processes, 
thereby contributing to disease progression and metastatic tumor developments. 
 
1.3.3 Matrix metalloproteinases (MMPs) 
1.3.3.1 The protein structure of MMPs – with particular emphasis on MMP-7 
The family of human matrix metalloproteinases consists of currently 24 members and belongs to 
the metzincin group of proteases (Page-McCaw et al., 2007), which besides MMPs includes the 
bacterial serralysins, astacins (BMP-1 and tolloid/tolloid-like proteases) and ADAMs/ADAMTSs 
(Bode et al., 1993). This enzyme superfamily is characterized by an essential Zn2+ at the active site 
and a conserved methionine-turn beneath the catalytic metal (Bode et al., 1993).  
MMPs are synthesized as prepro-proteins and contain a signal peptide at the N-terminus that 
directs the enzymes to the ER and is then removed, yielding the latent pro-enzymes (Lang et al., 
2001). Most MMPs are secreted in the extracellular space, however, some have a transmembrane 
domain with a short cytoplasmic tail (pro-MT-MMPs including proMMP-14, -15, -16, -24) or are 
anchored to the cell surface via glycosylphosphatidylinositol (GPI) linkages (proMMP-17 and 
proMMP-25) (Figure 7) (Nagase and Woessner, 1999).  
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Figure 7: The MMP-family  
The MMPs are expressed as pro-enzymes. The minimal domain MMPs (MMP-7 and MMP-26) are composed of the 
inhibitory pro-region and the catalytic domain. All other MMPs, except MMP-23, contain a hemopexin domain at 
the C-terminus, which is connected to the catalytic domain by a variable hinge region. MMP-23 has cysteine- and 
proline-rich regions instead of the hemopexin domain. The catalytic region of MMP-2 and MMP-9 additionally bears 
three fibronectin-like domains. The transmembrane and GPI-anchored MMPs as well as MMP-11 and MMP-28 
provide a furin-like recognition motif and can be intracellularly activated. The scheme is adapted from (Bode and 
Maskos, 2003). 
 
All MMPs possess an auto-inhibitory pro-domain, which maintains latency of MMPs, and a 
distinct adjacent catalytic domain (Massova et al., 1998). The pro-region holds a cysteine residue 
that forms a bridge with the Zn2+ at the active site and thereby prevents catalysis (Figure 7and 
Figure 8a) (Van Wart and Birkedal-Hansen, 1990). Enzymatic activity of MMPs requires the 
proteolytic cleavage of the pro-domain and subsequent access to the catalytically active center 
with the essential Zn2+ (Van Wart and Birkedal-Hansen, 1990). MMP-7 can be activated by 
MMP-3 and by several serine proteases such as trypsin, plasmin and leukocyte elastase which 
cleave at Glu94 (Figure 8a, highlighted in pink) and release a mature MMP-7 of approximately 
19 kDa (Figure 8a) (Imai et al., 1995). MMP-7 (EC 3.4.24.23) together with MMP-26 represent 
minimal domain MMPs and their structure is restricted to the pro-domain and the catalytic region 
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(Massova et al., 1998). All other MMPs, except MMP-23, additionally contain the hemopexin 
domain, a C-terminal four-bladed β-propeller structure that is connected to the catalytic domain 
by a variable hinge region (Piccard et al., 2007). This domain mediates protein-protein 
interactions and significantly contributes to substrate specificity, MMP localization, activation, 
internalization and degradation (Piccard et al., 2007). Moreover, three fibronectin-like domains 
are inserted in the catalytic region of MMP-2 and MMP-9 (Morgunova et al., 1999).   
The overall structure of the catalytic region is very similar among different MMPs and varies only 
in components framing the active site (Figure 8b, sV-hB loop and specificity loop) (Lang et al., 
2001). MMPs catalytic domains share a common ellipsoid shape with a small active site cleft from 
left to right, which creates a lower and an upper subdomain (Figure 8b) (Bode and Maskos, 
2003). The larger upper subdomain is dominated by a five-stranded β-sheet (sI-sV) and two long 
α-helices (hA and hB) connected by different loops (Figure 8b). Moreover, three Ca2+ and a 
second Zn2+ are involved in the structural organization (Figure 8b, blue and pink spheres). The 
active site region comprises the long horizontally extending α-helix B and the only antiparallel-
running strand sIV as well as the specificity loop in the lower subdomain (Figure 8b). These 
elements influence substrate recognition and in the case of MMP-7 provide a particularly 
hydrophobic surface (Lang et al., 2001). The essential Zn2+ in the catalytic center is coordinated 
by three histidine residues as part of a Zn2+-binding consensus sequence HEBXHXBGBXHZ 
(B: bulky hydrophobic amino acid, X: variable amino acid, Z: family specific amino acid), 
characteristic for the metzincin family, and a fixed water molecule that interacts in a hydrogen 
bond with the catalytic glutamate next to the first histidine (Lang et al., 2001). For most MMPs 
the last characteristic amino acid (Z) of the Zn2+-binding motif is a serine residue (Bode et al., 
1993) and the detailed sequence, representing this motif in the active site of MMP-7 is 
demonstrated in Figure 8a (turquoise). The α-helix B, which encompasses most of the Zn2+-
binding sequence, is followed by the highly conserved methionine-turn (Figure 8a and b). The 
protein chain runs through the specificity loop and then passes the α-helix C at the C-terminus in 
the lower subdomain (Figure 8b) (Lang et al., 2001). 
Besides proteolytic control due to this structural organization, MMP activity is determined by a 
complex regulatory network involving diverse transcriptional, translational and post-translational 
events (Sternlicht and Werb, 2001). 
 
 
a)       
        1 mrltvlcavc llpgslalpl pqeaggmsel qweqaqdylk rfylydsetk nansleaklk
       61 emqkffglpi tgmlnsrvie imqkprcgvp dvaeyslfpn spkwtskvvt yrivsytrdl
      121 phitvdrlvs kalnmwgkei plhfrkvvwg tadimigfar gahgdsypfd gpgntlahaf
      181 apgtglggda hfdederwtd gsslginfly aathelghsl gmghssdpna vmyptygngd
      241 pqnfklsqdd ikgiqklygk rsnsrkk  
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Figure 8: Amino acid sequence and tertiary structure of MMP-7.  
(a) Amino acid sequence of MMP-7. The newly synthesized preproMMP-7 consists of 267 amino acids. The 
signal peptide (grey) is cleaved in the ER, releasing latent proMMP-7 (18-267). The auto-inhibitory feature of the 
pro-domain requires the cysteine residue (red) in the so-called cysteine-switch (85-92) (red letters) that coordinates 
the catalytic Zn2+ and thereby inhibits MMP activity. Moreover, the pro-domain contains a peptidoglycan binding 
domain (blue letters) that allows interaction with glycoproteins such as PGs. Proteolytic cleavage of MMP-7 at Glu94 
(pink) yield the mature MMP-7 (95-267) (green letters). The characteristic Zn2+-binding motif (turquoise) including 
three histidines (His214, His218, His224) and the catalytic Glu215 is followed by the conserved Met232 (yellow) involved 
in the Met-turn (NCBI). (b) Tertiary structure of MMP-7 catalytic domain together with a bound inhibitor. 
The conserved secondary elements are demonstrated in yellow, whereas variations specific for MMP-7 are shown as 
orange ribbons. The active site cleft divides the catalytic domain in a small lower and a large upper subdomain. The 
upper subdomain is dominated by a five-stranded β-sheet (sI-sV) and two α-helices (hA and hB). After passing β-
strand sI, the protein chain continues in α-helix hA. A small loop connects hA with the β-strand sII which is 
followed by a surface loop leading to sIII. The β-strands sIII and sIV are linked via the S-loop that involves the 
structural Zn2+ (pink sphere) as well as one of the Ca2+-ions (blue sphere). The S-loop leads to the antiparallel-
running β-strand sIV which is situated at the edge to the catalytic center. Another surface loop connects sIV and sV, 
and the second Ca2+ (blue sphere) is located between the sIV-sV loop and the sII-sIII bridge. After β-strand sV the 
protein chain passes the variable sV-hB loop and enters the active site α-helix hB. The α-helix hB contains most of 
the Zn2+-binding motif and provides two histidine residues and the catalytic glutamate that interacts with the Zn2+-
coordinating water molecule. The third histidine is located beneath the helix and is followed by the methionine-turn. 
Finally, the chain runs through the MMP-dependent specificity loop into the C-terminal α-helix hC. Whereas the 
predominant structure elements are similar among different MMPs, they particularly differ in regions that frame the 
active site and ensure substrate specificity (e.g. sV-hB loop and specificity loop). Other MMPs are demonstrated by 
colored ribbons as follows: MMP-1 (red), MMP-2 (dark blue, lacking the fibronectin-like domain), MMP-3 (green), 
MMP-8 (grey), MMP-12 (yellow), MMP-13 (light blue) and MMP-14 (pink). The structure is adapted from (Lang et 
al., 2001).  
 
Introduction 
 
23 
 
1.3.3.2 Transcriptional regulation of MMP gene expression 
Expression of MMPs is to a large extent regulated at the transcriptional level, substantiated by a 
variety of cis-elements in the MMP-promoter regions and the susceptibility to numerous trans-
activators (Yan and Boyd, 2007). Besides categorization of MMPs according to their structural 
components, this enzyme family can also be subdivided on the basis of their promoters and the 
mechanisms involved in their gene expression. The majority of MMPs contains a TATA box as 
well as AP-1 and PEA3 binding sites in the promoter region completed by several other cis-
regulatory elements. Gene expression of a smaller group, comprising MMP-8, MMP-11 and 
MMP-21, is simpler and determined by a TATA box but lack of an AP-1 site, whereas MMP-2, 
MMP-14 and MMP-28 have AP-1 binding sites but are deficient in a TATA box (Yan and Boyd, 
2007). Expression regulation of the latter group is more susceptible to the family of SP-
transcription factors, which act through GC-motifs (Suske, 1999). The diversity of cis-acting 
elements in the MMP-promoter regions illustrates the ability to act in response to a number of 
extra- and intracellular signaling molecules and conditions (Yan and Boyd, 2007). AP-1 binding 
sites and/or PEA3 motifs presented in most MMPs confer transcription of these proteinases 
with the crucial response to cytokines and growth factors (e.g. interleukins, interferons, EGF, 
KGF, basic FGF, VEGF, PDGF, TNF-α, TGF-β; plus EMMPRIN (extracellular matrix 
metalloproteinase inducer)) (Fini et al., 1998). Trans-activation of MMP-transcription through 
certain promoter elements can also be induced or repressed following cellular stimulation with 
glucocorticoids, hormones or ECM proteins or upon processes such as integrin-signaling, cell 
stress or altered cellular contacts and cell shape (Fini et al., 1998). These signals in turn are 
referred to intracellular factors, including MAPK, NF-κB, STATs and Smads that eventually lead 
to enhanced expression of distinct transcription factors (Vincenti and Brinckerhoff, 2007). The 
prominent AP-1 and PEA3 sites in the MMP-promoters are additionally supplemented by 
responsive elements for NF-κB, C/EBP-β, Ets, retinoic acid, p53 and β-catentin, respectively, 
facilitating a complex interplay and a strict regulation of MMP gene expression (Yan and Boyd, 
2007).  
Moreover, in a variety of MMP-promoters DNA polymorphisms have been detected which can 
dramatically interfere with the regulatory capacity of responsive elements (Ye, 2000). Thus, a 
single nucleotide polymorphism (SNP) in the promoter of MMP-1 creates a new Ets recognition 
site close to an AP-1 site. This causes a remarkably increased MMP-1 expression and bears cancer 
promoting effects (Zhu et al., 2001). On the other hand, SNPs can disrupt binding sites and 
reduce promoter activity. A nucleotide transition in the MMP-2 promoter impedes binding of 
estrogen receptor-α, and thus, causes a reduced MMP-2 transcriptional response upon estrogen 
stimulation in MCF-7 breast cancer cells (Harendza et al., 2003). Finally, epigenetic regulations 
such as DNA methylation and chromatin remodeling contributes to MMP gene transcription (Ma 
et al., 2004; Couillard et al., 2006). However, despite numerous advances in understanding of 
MMP gene regulation, the cross-talk between the many signaling pathways, nuclear factors and 
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responsive elements that regulate transcription and might govern cell- and tissue-specific MMP 
expression are still poorly understood. 
 
1.3.3.3 Translational and post-translational MMP-regulation 
The extensive and precise regulation of MMP activity on the transcriptional level is 
complemented by post-transcriptional alterations. Thus, distinct AU-rich sequences (ARE) at the 
3’-untranslated region (UTR) recognize certain trans-acting proteins, thereby affecting mRNA 
stabilization (Huwiler et al., 2003; Rydziel et al., 2004). The 3’-UTR is additionally involved in 
recruitment of the mRNA to membrane-bound ribosomes and can mediate subsequent 
translation efficiency of a particular mRNA (Fahling et al., 2005). Once translated, the latent 
MMP proteins are usually constitutively secreted to the cell surface. Neutrophils, however, 
exhibited accumulation of MMP-8 and MMP-9 in intracellular vesicles and an induced secretion 
upon stimulation by inflammatory mediators (Sternlicht and Werb, 2001). As indicated above 
(cp. 1.3.3.1), latency of the secreted proteinases is maintained by the cysteine residue in the pro-
domain of MMPs, which functions as a fourth ligand for the Zn2+, and thus, blocks the catalytic 
center (Figure 7) (Van Wart and Birkedal-Hansen, 1990). Typically, MMPs become extracellularly 
activated by other MMPs or certain serine proteases and proMMP-2 represents the most 
complex mechanism involving MT1-MMP and TIMP-2 (tissue inhibitor of metalloproteinase-2) 
(Strongin et al., 1995). On the contrary, MT-MMPs as well as MMP-11 and MMP-28 provide a 
furin-like recognition motif and are already intracellularly processed and activated (Figure 7) (Pei 
and Weiss, 1995; Sternlicht and Werb, 2001). 
The complex regulatory mechanisms of MMP activity are augmented by the interaction with 
endogenous MMP inhibitors such as TIMPs (tissue inhibitor of metalloproteinases) and α2-
macroglobulin. The α2-macroglobulin is a strong inhibitor of MMPs, inducing an irreversible 
clearance of MMPs by receptor-mediated endocytosis (Woessner, 1991). Whereas α2-
macroglobulin is an abundant plasma protein, TIMPs act more locally in a cell- and tissue-specific 
manner. TIMPs comprise a family of so far four protease inhibitors of about 20-30 kDa that 
interact with active MMPs (except proMMP-2; (Strongin et al., 1995)) in a 1:1 stoichiometry  
(Edwards, 2001). Similar to MMPs, TIMPs underlie a tight gene regulation and exhibit a tissue-
specific pattern of protein expression (Edwards, 2001). Moreover, TIMPs significantly differ in 
their ability to bind and inhibit diverse MMPs. Whereas the N-terminal domain bears the 
inhibitory function, the C-terminus influences substrate specificity (Willenbrock and Murphy, 
1994). As already indicated by the function of α2-macroglobulin, MMPs are finally influenced by 
catabolic mechanisms. Whereas α2-macroglobulin induces MMP-clearance by receptor-mediated 
endocytosis, distinct cleavage can completely inactivate MMPs and signal their degradation, or 
interfere with normal enzyme features by alteration of their substrate specificity, cellular 
localization or TIMP-binding ability (Sternlicht and Werb, 2001). 
Introduction 
 
25 
 
Thus, MMP activity is controlled by an enormous regulatory machinery, indicating the 
importance of these enzymes and suggesting severe consequences of impaired signaling 
processes.  
 
1.3.3.4 Matrix metalloproteinases are multifunctional proteins 
Though MMPs were originally thought to be exclusively responsible for ECM degradation, a 
variety of additional mechanisms are now known that require MMPs (Sternlicht and Werb, 2001; 
Page-McCaw et al., 2007). Alteration of structural ECM compounds still represents a major task 
of MMPs, permitting ECM remodeling during physiological development and creating space for 
cells to migrate during wound healing (Vu et al., 1998; Kyriakides et al., 2009). But MMP activity 
also contributes to cellular migration and invasion during inflammation and pathological or 
metastatic events by degradation of the ECM and disruption of intercellular junctions or cell 
adhesion receptors (Page-McCaw et al., 2007). Thus, MMP-7 demonstrates strong proteolytic 
activity against elastin fibers in vivo and is known to contribute to atherosclerotic phenotypes 
(Filippov et al., 2003). Besides cleavage of the ECM, MT1-MMP is capable of degrading tissue 
transglutaminase and thereby impedes cellular adhesion on fibronectin (Belkin et al., 2001). 
Moreover, MMPs influence cell-cell and cell-ECM interactions by the generation of fragments 
with a different biologic activity (Noe et al., 2001). Proteolysis of E-cadherin by MMP-3 and 
MMP-7 creates a soluble protein fragment that affects E-cadherin function, looses cell 
aggregation and favors cellular invasion (Noe et al., 2001). Cleavage of fibrillar-associated 
collagen IV by MMP-2 reveals otherwise cryptic RGD domains, which are involved in integrin-
binding and promote angiogenesis and tumor survival (Xu et al., 2001). Likewise, MMP-2 
exposes a hidden signal on laminin-5 that acts promigratory for breast epithelial cells (Giannelli et 
al., 1997).  
Moreover, MMPs play a key role in the regulation of activity and availability of diverse signaling 
molecules such as cytokines, chemokines, growth factors or hormones (Sternlicht and Werb, 
2001). MMPs can provoke the release of growth factors and convert them into active molecules 
that in turn trigger intracellular signal transduction and cellular behavior (Fowlkes et al., 1995; 
Hao et al., 2004; Lee et al., 2005). Thus, MMP-9 is anchored by the HSPG CD44 to the cell 
surface and proteolytically activates latent TGF-β (Yu and Stamenkovic, 2000). Moreover, 
cleavage of a distinct matrix-bound isoform of the vascular endothelial growth factor (VEGF) by 
MMPs release a soluble fragment that triggers vascular dilation (Lee et al., 2005). An increase of 
functional insulin-like growth factors (IGF) is indirectly regulated by inactivation of their binding 
proteins (IGFBPs) through MMPs and results in an increased cell proliferation (Fowlkes et al., 
1995). MMP-7 affects the generation of soluble ligand (sFasL) for the Fas death receptor and 
thereby increases apoptosis in the first place but finally favors selection for apoptotis-resistant 
cells, provoking mammary tumorigenesis (Vargo-Gogola et al., 2002b). MMP-cleavage can also 
inactivate certain chemoattractants and thereby has a great impact on wound healing and the 
inflammatory response (McQuibban et al., 2002). 
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Besides direct modification of signaling molecules, MMPs also act on the respective cell surface 
receptors e.g. growth factor receptors or cytokine receptors, and thereby alter cellular signal 
transduction pathways. Fibroblast growth factor (FGF) activities are affected by MMP-2-initiated 
ectodomain shedding of FGF receptor type 1 (FGFR1). The soluble extracellular domain still 
bears FGF binding capacity but is no longer capable of direct transactivation of intracellular 
mechanisms (Levi et al., 1996). MMP-9-mediated degradation of the interleukin-2 receptor α (IL-
2Rα) impedes recruitment of functional T cells and provides cancer cells with an effective 
mechanism to suppress the immune response in tumor tissues (Sheu et al., 2001). As already 
mentioned above, MMPs are involved in activation of latent metalloproteinases and other pro-
enzymes which may initiate proteolytic cascades that significantly intensify the initial signal 
(Mochizuki et al., 2004).   
Moreover, interaction and/or direct cleavage of extracellular proteins such as PGs significantly 
influence the impact of MMPs on signaling molecules. Thus, proteolysis of decorin by MMPs 
abrogates the reservoir for TGF-β and consequentially induces TGF-β mediated processes (Imai 
et al., 1997). The HSPG CD44 indirectly influences cell signaling by facilitating localization of 
MMP-7 in close proximity to its substrate heparin-binding epidermal growth factor-like growth 
factor (HB-EGF) (Kajita et al., 2001; Yu et al., 2002). The recruitment of MMP-7 to the cell 
surface plays an essential role in ectodomain shedding of HB-EGF and emphasizes an important 
regulatory function of MMP-7 for HB-EGF signaling (Yu et al., 2002). The proteolytic cleavage 
of HB-EGF by MMP-7 results in the release of a soluble fragment (sHB-EGF) which in turn can 
transactivate intracellular signaling mechanisms via the EGF-receptors ErbB4 and ErbB1 (Lynch 
et al., 2007). Remarkably, CD44 not only anchors MMP-7 and HB-EGF to the cell surface but 
also associates with ErbB4 and ErbB1 to ensure an effective signal transduction (Yu et al., 2002).  
In general, MMPs are less important for embryogenesis, but are crucial for postnatal 
development and in adult tissues, conferring the organism with essential tissue and ECM 
remodeling systems involved in bone formation, blood-vessel refinement or mammary gland 
development (Page-McCaw et al., 2007). MMP-7 predominantly bears crucial physiological 
functions in the matured organism and mediates ECM-restructuring and protein-processing 
related to wound healing and innate immunity (Page-McCaw et al., 2007). Moreover, several 
human tumors, including breast cancers, demonstrate significant overexpression of MMP-7, 
suggesting deregulated MMP-7 to be a crucial factor for tumorigenesis (Wilson and Matrisian, 
1996). Several but definitely not all substrates of MMP-7 have been identified and the list of 
interacting proteins is growing. However, the detailed signal transduction pathways and their 
complex interplay are largely unknown and require further investigations.  
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1.4 Aim and concept of this study 
Previous studies revealed that HMEC have a limited lifespan and underlie a process termed 
cellular senescence. Some fundamental aspects of the HMEC aging process such as a premature 
stress-associated senescence (stasis), cell cycle inhibition due to telomere erosion and the 
discrimination of these steps using p16INK4a, respectively, were investigated. Besides considerable 
restructuring of the cell shape, senescence significantly interferes with cellular functionality. It is 
known that in senescent cells particularly extracellular secreted enzymes such as MMPs differ 
notably from those sequestered by young cells. Different effects of these enzymes on cancer cells 
have been described but the detailed mechanisms how the senescence-associated secretome may 
influence HMEC themselves remained obscure.  
The focus of the present study will be on proteins involved in cell-cell and cell-matrix 
communications and their impact on the aging process of HMEC to verify a potential role of the 
extracellular microenvironment during cellular senescence.  
An initial characterization of the HMEC cultures regarding p16INK4a expression, cell cycle 
regulation and SA β-gal activity will be required to identify the senescent state of the cells. 
Besides screening of distinct cell surface-associated glycoproteins, expression of extracellular 
MMPs will be analyzed to identify potential candidates that are affected by and may contribute to 
cellular senescence. Subsequent siRNA-targeting and down-modulation of the respective protein 
should reveal its function and potential relevance for the aging process of HMEC, while 
unraveling certain associated signal transduction mechanisms.  
Taking into consideration that MMPs significantly contribute to ECM degradation and 
remodeling, potential alterations of ECM compounds should be examined. Protein levels of 
distinct ECM-precursor proteins as well as the expression and activity of certain enzymes 
involved in ECM maturation should be analyzed. A deregulation of these proteins could provide 
new insights in matrix-associated signaling mechanisms and their contribution to cellular 
senescence of HMEC. 
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2 Material and Methods 
2.1 Material 
2.1.1 Cell culture 
Cell culture material Manufacturer
Primary normal human mammary epithelial 
cells (HMEC) 
MCF-7 mammary gland adenocarcinoma cells  
 
Mammary epithelial basal medium (MEBM) 
MEBM-Supplement 
Dulbecco's Modified Eagle Medium (DMEM) 
Fetal calf serum (FCS) 
Penicillin/streptomycin 
L-glutamine 
Sodium pyruvate 
Trypsin/EDTA (0.05%) 
Detach-Kit 2: 
HepesBSS-Buffer 
Trypsin/EDTA (0.025%/0.01%) 
Trypsin neutralization solution (0.05%) 
BioWhittaker, Walkersviell, USA 
(Lot #1F1012) 
American Type Culture Collection (ATCC), 
Manassas, USA  
PromoCell, Heidelberg, Germany 
PromoCell, Heidelberg, Germany 
Invitrogen, Karlsruhe, Germany 
Biochrom, Hannover, Germany 
Biochrom, Hannover, Germany 
PAA Laboratories, Cölbe, Germany 
PAA Laboratories, Cölbe, Germany 
Invitrogen, Karlsruhe, Germany 
PromoCell, Heidelberg, Germany 
 
 
 
 
2.1.2 Kits  
Kit Manufacturer
BCA Protein Assay Reagent Kit 
CINtec Cytology Kit 
Cervatec p16INK4a ELISA 
CyStain DNA 2 steps 
HMEC Nucleofector Kit 
Roti Blue 
Senescence-associated β-Galactosidase 
Staining Kit 
Western Lightning Chemiluminescence 
Reagent Plus 
Pierce, Bonn, Germany
mtm Laboratories, Heidelberg, Germany 
mtm Laboratories, Heidelberg, Germany 
Partec, Münster, Germany 
Amaxa (Lonza), Köln, Germany 
Carl Roth, Karlsruhe, Germany 
Cell Signaling, Danvers, USA 
 
Perkin Elmer, Boston, USA 
 
Material and Methods 
 
29 
 
2.1.3 Antibodies 
Antibody (Ab) 
(IF = immunofluorescence;  
WB = Western blot; F = Flow cytometry) 
Manufacturer
Negative control FITC IgG2a  
(F: 15µl/1x106 cells) 
Dual negative control FITC/R-PE IgG1  
(F: 15µl/1x106 cells) 
Monoclonal FITC-conjugated mouse IgG2a 
anti-CD24 Ab. (F: 15µl/1x106 cells) 
Monoclonal R-PE- conjugated mouse IgG1 
anti-CD29 Ab (F: 15µl/1x106 cells) 
Monoclonal FITC- conjugated mouse IgG1 
anti-CD44 Ab (F: 15µl/1x106 cells) 
Monoclonal FITC- conjugated mouse IgG1 
anti-CD227 Ab (F: 15µl/1x106 cells) 
Monoclonal mouse anti-β-actin Ab (clone AC-
15) (WB 1:15.000) 
Monoclonal mouse anti-elastin Ab 
(clone BA-4) (IF: 1:15) 
Monoclonal mouse anti-fibrillin-1 Ab (clone 
11C1.3) (IF: 1:15) 
Polyclonal rabbit anti-Fra-1 Ab (clone R-20) 
(WB: 1:1000) 
Monoclonal mouse anti-GAPDH Ab  
(clone 6C5) (WB 1:1.000) 
Monoclonal mouse anti-HB-EGF Ab  
(clone E-10) (WB: 1:100) 
Polyclonal goat anti-HB-EGF Ab  
(clone C-18) (IF: 1:10) 
Polyclonal rabbit anti-LOX Ab (ab31238) 
(WB: 1:200) 
Polyclonal rabbit anti-LOXL1 Ab (clone H-
165) (WB: 1:100) 
Polyclonal rabbit anti-MMP-1 Ab (SA-102) 
(WB: 1:2000) 
Monoclonal mouse anti-MMP-2 Ab (clone 
2C1) (WB: 1:500) 
DakoCytomation, Glostrup, Denmark 
 
DakoCytomation, Glostrup, Denmark 
 
Becton Dickinson Pharmingen, Heidelberg, 
Germany 
Becton Dickinson Pharmingen, Heidelberg, 
Germany 
Becton Dickinson Pharmingen, Heidelberg, 
Germany 
Becton Dickinson Pharmingen, Heidelberg, 
Germany 
Sigma Aldrich, Taufkirchen, Germany 
 
Santa Cruz Biotechnology, Santa Cruz, USA 
 
Thermo Fisher Scientific, Fremont, USA 
 
Santa Cruz Biotechnology, Santa Cruz, USA 
 
Santa Cruz Biotechnology, Santa Cruz, USA 
 
Santa Cruz Biotechnology, Santa Cruz, USA 
 
Santa Cruz Biotechnology, Santa Cruz, USA 
 
Abcam, Cambridge, USA 
 
Santa Cruz Biotechnology, Santa Cruz, USA 
 
Biomol, Hamburg, Germany 
 
Biomol, Hamburg, Germany 
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Antibody (Ab) 
(IF = immunofluorescence;  
WB = Western blot; F = Flow cytometry) 
Manufacturer
Polyclonal rabbit anti-MMP-7 Ab (SA-105) 
(WB: 1:1000) 
Monoclonal mouse anti-MMP-7 Ab (clone 
111433) (IF: 1:20; WB: 1:400) 
Polyclonal rabbit anti-MMP-9 Ab (SA-106) 
(WB: 1:1000) 
Polyclonal rabbit anti-tropoelastin Ab  
(PR398) (WB: 1:2000; IF: 1:20) 
Alexa Fluor 488 chicken anti-goat IgG  
(IF: 1:1000) 
Alexa Fluor 488 goat anti-rabbit IgG  
(IF: 1:1000) 
Alexa Fluor 568 goat anti-mouse IgG  
(IF 1:1000) 
Hoechst 33258 (IF: 1:200) 
HRP-conjugated sheep anti-mouse IgG  
(WB 1:10000) 
HRP-conjugated donkey anti-rabbit IgG  
(WB 1:7500 - 1:15000) 
HRP- conjugated donkey anti-goat IgG  
(WB 1:25.000) 
Novus Biologicals, Littleton, USA 
 
RnD Systems, Minneapolis, USA 
 
Biomol, Hamburg, Germany 
 
Elastin Products Company (EPC), Owensville, 
USA 
Invitrogen, Karlsruhe, Germany 
 
Invitrogen, Karlsruhe, Germany 
 
Invitrogen, Karlsruhe, Germany 
 
Invitrogen, Karlsruhe, Germany 
GE Healthcare, Freiburg, Germany 
 
GE Healthcare, Freiburg, Germany 
 
Santa Cruz Biotechnology, Santa Cruz, USA 
 
2.1.4 Small interfering RNAs (siRNAs) 
siRNA Manufacturer
AllStars Negative Control siRNA 
Negative Control siRNA-AF488 
Hs_MMP7_3_HP siRNA:  
TGG ACG GAT GGT AGC AGT CTA 
Hs_MMP7_4_HP siRNA: 
CTG CAT TTC AGG AAA GTT GTA 
Hs_ HBEGF_5_HP siRNA: 
AGC ACT GGC CAC ACC AAA CAA 
Hs_HBEGF_6_HP siRNA: 
GTG CTG GAT TTG ATG AGT TAA 
Qiagen, Hilden, Germany 
Qiagen, Hilden, Germany 
Qiagen, Hilden, Germany 
 
Qiagen, Hilden, Germany 
 
Qiagen, Hilden, Germany 
 
Qiagen, Hilden, Germany 
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2.1.5 Chemicals 
Industry standard chemicals were used as grade ‘pro analysis’ and were obtained from the 
companies Merck (Darmstadt, Germany), J.T. Baker (Deventer, Netherlands), Sigma Aldrich 
(Taufkirchen, Germany) and Carl Roth (Karlsruhe, Germany), respectively. Specific reagents and 
chemicals were purchased from the following companies: 
 
Chemical Manufacturer
Albumin standard 
Ammonium persulfate (APS) 
Amplex Red Reagent 
β-aminopropionitrile (BAPN) fumarate salt  
CHAPS 
1,5-Diaminopentane 
Dimethyl sulfoxide (DMSO) 
Dithiothreitol 
Dried skimmed milk 
Horseradish peroxidase (HRP) 
Hydrogen peroxide  
Low-melting point agarose 
Nonidet NP-40 
Pharmalyte 3-10 
Phenylmethansulfonyl fluoride (PMSF) 
Precision Plus Protein all blue standard 
ProLong Gold Antifade  
Roti Blue 
Rotiphorese Gel 40 (37,5:1) 
Sodium tetraborate 
N,N,N’,N’-tetramethylethylendiamine 
(TEMED) 
Tween 20 
Urea 
Pierce, Rockford, USA
Serva, Heidelberg, Germany 
Invitrogen, Karlsruhe, Germany 
Sigma Aldrich, Taufkirchen, Germany 
GE Healthcare, Freiburg, Germany 
Sigma Aldrich, Taufkirchen, Germany 
Sigma Aldrich, Taufkirchen, Germany 
Carl Roth, Karlsruhe, Germany 
Marvel, Dublin, Ireland 
Sigma Aldrich, Taufkirchen, Germany 
Sigma Aldrich, Taufkirchen, Germany  
Sigma Aldrich, Taufkirchen, Germany  
Roche Diagnostics, Mannheim, Germany 
GE Healthcare, Freiburg, Germany 
Sigma Aldrich, Taufkirchen, Germany 
BioRad, Munich, Germany 
Invitrogen, Karlsruhe , Germany 
Carl Roth, Karlsruhe, Germany 
Carl Roth, Karlsruhe, Germany 
Sigma Aldrich, Taufkirchen, Germany 
Sigma Aldrich, Taufkirchen, Germany 
 
Carl Roth, Karlsruhe, Germany 
Carl Roth, Karlsruhe, Germany 
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2.1.5.1 Sterile 1x phosphate buffered saline (PBS) pH 7.4 
10x PBS pH 6.8 
NaCl 
KH2PO4 
Na2HPO4 
KCl 
1.37 M 
0.01 M 
0.08 M 
0.027 M 
 
The 10-fold concentrated buffer solution (10x PBS) was diluted 1:10 with ddH2O and portioned 
in 100ml-flasks. The buffer was subsequently autoclaved at 121°C for 20 min. After cooling 
down to room temperature, sterile 1x PBS was stored at 4°C. 
In the following text PBS is always referred to 1x PBS. 
 
2.1.6 Instruments and devices 
Instruments and devices Manufacturer
Autoclave LVSA 50/70
Autoclave HST 6x6x6 
Centrifuge 5415 C, 5415 D, 5415 R, 5810 R 
Electrophoresis Power Supply EPS301 
Fluoroskan Ascent Fl 
Freezing container 
 
Galaxy Flow cytometer 
Glassware pipettes  
Incubator 
Laboratory device cleaner G7883 CD  
Microscope Leica AF6000 
Microscope Keyence BZ-8100 
Microscope Olympus IX50 
Mini-Protean 3 Electrophoresis System 
Mixer Reax Top 
Multiscan EX  
Neubauer chamber 
Nucleofector 
pH-meter 766 Calimatic 
Pipette cleaner 
Power supply PAC200 
Rotation device 
Sterile workbench  
Zirbus, Bad Grund, Germany 
Zirbus, Bad Grund, Germany 
Eppendorf, Hamburg, Germany 
GE Healthcare, Freiburg, Germany  
Thermo Fisher Scientific, Dreieich, Germany 
(Nalgene) Thermo Fisher Scientific, 
Langenselbold, Germany 
Dako, Hamburg, Germany 
Brand, Wertheim, Germany 
Heraeus, Hannover, Germany 
Miele, Gütersloh, Germany 
Leica, Wetzlar, Germany 
Keyence, Neu-Isenburg, Germany 
Olympus, Hamburg, Germany 
Bio-Rad, Munich, Germany 
Heidolph Instruments, Schwabach, Germany 
Thermo Fisher Scientific, Dreieich, Germany 
Brand, Wertheim, Germany 
Amaxa (Lonza), Cologne, Germany 
Knick, Berlin, Germany 
Hölzel, Hörkofen, Germany 
Bio-Rad, Munich, Germany 
GfL, Burgwedel, Germany 
Heraeus, Hannover, Germany 
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Instruments and devices Manufacturer
Sterilizer, model 440 
Shaker Duomax 1030 
TE 22 Mini Tank Transfer Unit 
TE 62 Tank Transfer Unit 
Thermo mixer 546 plus 
Vertical electrophoresis system 
Vi-Cell 
X-ray Processor XP505 
Memmert, Schwabach, Germany 
Heidolph Instruments, Schwabach, Germany 
GE Healthcare, Freiburg, Germany 
GE Healthcare, Freiburg, Germany 
Eppendorf, Hamburg, Germany 
PEQLAB Biotechnologie, Erlangen, Germany 
Beckman Coulter, Krefeld, Germany 
3M, Neuss, Germany 
 
2.1.7 Consumable supplies 
Consumable supplies Manufacturer
Blotting paper 
Cell culture dishes, flasks, microtiterplates 
 
Centrifugal filter devices (Amicon Ultra-4 
Centrifugal Filter Units with an Ultracel-10 
membrane) 
Cryo.S vials 
Cover slips 
Disposable syringe Omnifix 40 Solo  
Hybond-C Extra 
Hyperfilm 
Needles (0.4, 0.6, 0.8) 
Microscope slides superfrost plus 
Tubes (0.5 ml, 1.5 ml, 2.0 ml)  
Silanized slides 
Omnilab, Bremen, Germany 
(Nunc) Thermo Fisher Scientific, 
Langenselbold, Germany 
Millipore, Schwalbach, Germany 
 
 
Greiner Bio-One, Frickenhausen, Germany 
Thermo Fisher Scientific, Dreieich, Germany 
Braun Petzold, Melsungen, Germany 
GE Healthcare, Freiburg, Germany 
GE Healthcare, Freiburg, Germany 
Becton Dickinson, Heidelberg, Germany 
Thermo Fisher Scientific, Dreieich, Germany 
Eppendorf, Hamburg, Germany 
Dako, Hamburg, Germany 
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2.1.8 Software 
Software Manufacturer
Adobe Photoshop 
Ascent Software v.2.6 
 
Endnote 
FloMax Flow Cytometry Software 
ImageJ 
Keyence BZ-8100 Software 
LAS AF 
Microsoft Office 
 
MultiCycle Software 
NCBI 
Adobe Systems, Munich, Germany 
Thermo Electron Corporation, Dreieich, 
Germany 
Thomson Reuters, Carlsbad, USA 
Partec, Münster, Germany 
NIH, Bethesda, USA 
Keyence, Neu-Isenburg, Germany 
Leica, Wetzlar, Germany 
Microsoft Deutschland, Unterschleißheim, 
Germany 
Phoenix Flow Systems, San Diego, USA 
National Center for Biotechnology 
Information, Bethesda, MD, USA 
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2.2 Methods 
2.2.1 Cell biology 
2.2.1.1 Cell culture of primary human mammary epithelial cells (HMEC) 
Primary cultures of human mammary epithelial cells (HMEC) were isolated from a 50 year old 
Caucasian female and commercially provided by BioWhittaker Inc. as culture passage 7 
(Lot #1F1012). HMEC were tested positive for cytokeratins 14 and 18 and negative for 
cytokeratin 19 and vimentin, respectively. They were performance tested and tested negative for 
HIV-1, hepatitis B & C, mycoplasma, bacteria, yeast and fungi. 
HMEC were seeded at 2,500 cells/cm2 and cultured in mammary epithelial cell basal medium 
(PromoCell). The HMEC medium (500 ml) was supplemented with 2 ml of bovine pituitary 
extract (13 mg/ml), 0.5 ml of hydrocortisone (0.5 µg/ml), 0.5 ml of human recombinant 
epidermal growth factor (10 µg/ml), 0.5 ml insulin (5 mg/ml), and 0.5 ml gentamycin 
(50 µg/ml)/amphotericin-B (50 µg/ml). The cells were cultured at 37°C in a humidified 
atmosphere with 5 % CO2 and the appropriate medium of each culture was replaced every two to 
three days. 
2.2.1.2 Subculture of primary HMEC 
At subconfluent conditions, residual medium was removed from the cells by washing with 
HepesBSS buffer (PromoCell) and HMEC were incubated with 0.025 %/0.01 % trypsin/EDTA 
(PromoCell) for about 7 min/37°C until they detached. Thereafter, immediate addition of trypsin 
neutralization solution (TNS) from soybean was required to inactivate the trypsin followed by 
subsequent centrifugation (220 g/6 min). The pelleted cells were resuspended in new medium at 
about 104 cells/ml and cultured further on in the next passage number. 
2.2.1.3 Stimulation of HMEC with β-aminopropionitrile (BAPN) 
HMEC populations during cellular senescence were cultured in the presence and absence of the 
LO-inhibitor BAPN for 12 days. HMEC were seeded in passage 16 on cover slips in a cell 
culture dish. After two days of culture, the cells were stimulated with 2 mM BAPN, whereas the 
appropriate control populations were cultured without BAPN. The respective medium (with or 
without BAPN) was changed every two days. After 12 days of culture, the control populations 
and BAPN-treated HMEC were fixed with 4 % paraformaldehyde and processed for 
immunofluorescence detection as described below (2.2.2.2). 
2.2.1.4 Cell culture of MCF-7 mammary gland adenocarcinoma cells 
Human MCF-7 mammary gland adenocarcinoma cells originally isolated from a 69 year old 
Caucasian woman with several characteristics of differentiated mammary epithelium (Soule et al., 
1973) were derived from the American Type Culture Collection (ATCC #HTB-22) as 
passage 146 or earlier and cultured in DMEM-medium (Invitrogen), including 10 % (v/v) heat-
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inactivated fetal calf serum (FCS) (Biochrom), 2 mM L-glutamine (Invitrogen), 1 mM sodium 
pyruvate (Invitrogen) and 1 mM penicillin/streptomycin (Invitrogen). The cells were cultured at 
37°C in a humidified atmosphere with 5 % CO2 and the appropriate medium of each culture was 
replaced every two to three days. 
2.2.1.5 Subculture of MCF-7 cell line 
At subconfluent conditions, the conditioned medium was collected and residual medium was 
removed from the cells by washing with PBS. MCF-7 cells were incubated with 
0.05 % trypsin/EDTA (Invitrogen) for about 5 min/37°C until they detached. Thereafter, 
immediate addition of conditioned medium, containing 10 % FCS, was required to inactivate the 
trypsin followed by subsequent centrifugation (350 g/6 min). The pelleted cells were resuspended 
in new DMEM medium at about 5 x 104 cells/ml and cultured further on in the next passage 
number. 
2.2.1.6 Cryostorage of cells in liquid nitrogen 
HMEC and MCF-7 were harvested by trypsinization. After determination of the cell number, 
about 1 x 106 HMEC and 3 x 106 MCF-7 cells, respectively, were transferred in a 2 ml-cryogenic 
vial (Greiner) and supplemented with 10 % (v/v) FCS and 10 % (v/v) DMSO. Vials were placed 
in a freezing container (Nalgene) and cooled at a rate of 1°C/min in the -80°C freezer to ensure 
optimal cryopreservation. Finally, the vials were transferred in a liquid nitrogen tank for long 
term storage. 
2.2.1.7 Determination of cell number and viability 
After trypsinization, cell number and viability were determined by trypan blue exclusion either 
using the Neubauer chamber or by automatic measurement in the Vi-Cell (Beckman Coulter).  
2.2.1.8 Determination of population doublings 
The proliferative capacity of a cell population can be determined by calculating the population 
doublings (PD) per day according to the formula: 
t
NNdayPD ih 1*
2log
loglog
/ ⎟⎟⎠
⎞
⎜⎜⎝
⎛ −
=  
Ni = initial cell number 
Nh = cell number harvested 
t = time of cell culture in days 
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2.2.1.9 Senescence-associated β-galactosidase assay (SA β-gal) 
About 1 x 104 HMEC were seeded in a 24-well plate (nunc, Thermo Fisher Scientific) and 
cultured for the appropriate time. The cells were fixed with 1x Fixative Solution, containing 20 % 
formaldehyde and 2 % glutaraldehyde (Cell Signaling Technology), and stained against 
senescence-associated β-galactosidase (SA β-gal) (Cell Signaling Technology) for 24 h/37°C in 
the dark according to the manufacturer’s protocol and recommendations. The staining was 
proportional to the amount of substrate (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside) 
enzymatically transformed. Following two washes with PBS the differentially-stained cell cultures 
were documented by phase contrast microscopy using the Olympus imaging software cellB 
(Olympus) and quantified by counting. 
2.2.1.10 Cell cycle analysis 
Cell cycle analysis by flow cytometry is based on the fluorescent staining of nuclear DNA. After 
trypsinization, about 1 x 105 HMEC were fixed in 70 % (v/v) ice-cold ethanol at 4°C for 24 h. 
Thereafter, the fixed cells were washed twice with PBS, stained with CyStain DNA 2 step kit 
according to the manufacturer’s protocol (Partec) and filtered through a 50 µm filter. The 
samples were analyzed in a Galaxy flow cytometer (Dako) using FloMax analysis software 
(Partec) and the MultiCycle cell cycle software (Phoenix Flow Systems). Subsequently, the 
particular cell cycle phases were quantified using FloMax analysis software. The population with 
degenerated DNA was defined as the rate of dying or dead cells, whereby 8N DNA represented 
aberrant mitosis. 
2.2.1.11 Analysis of surface marker expression by flow cytometry 
HMEC P12 to P16 and the cancer cell line MCF-7 were trypsinized and fixed in 70 % (v/v) ice-
cold ethanol at 4°C for 24 h. Thereafter, the cells were washed twice with PBS and incubated 
with the appropriate fluorescence-labeled antibodies, CD24, CD29, CD44, CD227 (all from BD 
Biosciences) and the isotype-specific negative controls (DakoCytomation), for 30 min at room 
temperature. After two additional washing steps, the cells were measured with a Galaxy flow 
cytometer (Dako) using FloMax analysis software (Partec). The amount of cell surface marker 
expression was proportional to the fluorescence intensity. 
2.2.1.12 siRNA-transfection 
Transfection of HMEC and MCF-7, respectively, was performed according to the manufacturer’s 
protocol (amaxa). Briefly, 1 x 106 HMEC P11 or 2 x 106 MCF-7 were harvested by trypsinization 
and resuspended in 100 µl HMEC Nucleofector Solution (amaxa). The cell suspension was mixed 
with 1 µg siRNA and 2 µg pmaxGFP, respectively, placed in a sterile electroporation cuvette and 
subjected to program X-005 using the Nucleofector II (amaxa). For MMP-7 gene silencing the 
following sequences were targeted: TGG ACG GAT GGT AGC AGT CTA (Hs_MMP7_3_HP 
siRNA) and CTG CAT TTC AGG AAA GTT GTA (Hs_MMP7_4_HP siRNA). Moreover, 
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HB-EGF was targeted using: AGC ACT GGC CAC ACC AAA CAA (Hs_ HBEGF_5_HP 
siRNA) and GTG CTG GAT TTG ATG AGT TAA (Hs_HBEGF_6_HP siRNA). AllStars 
Negative Control siRNA was used as a negative control and Negative Control siRNA-AF488 as a 
green fluorescence-labeled negative control (all from Qiagen), respectively. Both negative siRNAs 
have no homology to any known mammalian gene. pmaxGFP was provided with the HMEC 
Nucleofector Kit (amaxa) and served as a positive control. After transfection, the cells were 
immediately transferred into pre-warmed culture medium. To evaluate the transfection efficiency, 
HMEC controls and cells transfected with Negative Control siRNA-AF488 were harvested after 
5 h, washed twice with PBS and subjected to the Galaxy flow cytometer (Dako) using FloMax 
analysis software (Partec). HMEC transfected with pmaxGFP (amaxa) were analyzed by 
fluorescence microscopy (Olympus) after 48 h. 
To prolong the transient down-modulation of MMP-7 and HB-EGF, additional transfections 
with the particular siRNA were performed after 48 h. Therefore, the MMP-7 and HB-EGF 
transfected HMEC were harvested by trypsinization, transfected again with 1 µg siRNA as 
described above and incubated for another 48 h. For Western blot and cell cycle analysis, the 
transfected cells were harvested at the indicated time points post transfection. At the same time, 
cells were fixed for SA β-gal staining (Cell Signaling Technology) (2.2.1.9). 
2.2.1.13 Cell lysis 
Lysis buffer pH 7.5 
Tris 
NaCl 
EDTA 
EGTA  
Sodium pyrophosphate 
β-glycerolphosphate 
Sodium metavanadate 
Leupeptin 
Triton X-100 
Nonidet P-40 
PMSF 
20 mM 
150 mM  
1 mM 
1 mM 
2.5 mM 
1 mM 
1 mM 
1 µg/ml 
1 % (v/v) 
0.5 % (v/v) 
1 mM 
 
HMEC and MCF-7 populations were harvested by trypsinization and the cell number was 
determined by trypan blue exclusion. Cells were washed with PBS and collected by centrifugation 
(220g/6 min). The cell pellets were either shock frozen in liquid nitrogen and stored at -80°C or 
immediately processed. Cell pellets which were stored at -80°C were thawed on ice and 
homogenized in the appropriate volume of ice-cold lysis buffer pH 7.5. After centrifugation 
(14,000 g/10 min/4°C), the resulting supernatant with the appropriate protein homogenate was 
subjected to a protein quantification measurement using the BCA protein assay (Pierce). 
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2.2.2 Immunocytochemical methods 
2.2.2.1 p16INK4a assay 
The p16INK4a assay is based on the qualitative immunocytochemistry method and was performed 
according to the CINtec Cytology Kit protocol (mtm laboratories). Briefly, about 1 x 104 HMEC 
were seeded on glass slides and cultured in mammary epithelial cell basal medium (PromoCell). 
The cells were fixed in 96 % (v/v) ethanol, rehydrated and initially incubated for 15 min at 95°C 
in the epitope retrieval solution provided with the kit. Including several washing steps with wash 
buffer (mtm laboratories), the cells were incubated with peroxidase blocking reagent, primary 
anti-human p16INK4a antibody and a HRP-conjugated secondary antibody. The chromogen 
solution was based on 3,3’-diaminobenzidine (DAB) and indicated the over-expression of 
p16INK4a by a brown staining of the cells. Haematoxylin was used as a counterstain. Phase contrast 
microscopy was performed with an Olympus IX50 microscope using the Olympus imaging 
software cellB (Olympus). 
2.2.2.2 Immunofluorescence detection of MMP-7 and HB-EGF 
For immunofluorescence, 1x104 HMEC were seeded on cover slips. The cells were fixed with 
4 % (v/v) paraformaldehyde for 5 min at room temperature. After neutralization with 1x TBS 
and permeabilization with 0.1 % (v/v) Triton X-100 in PBS, unspecific binding sites were 
blocked with 3 % BSA/PBS for 30 min at 37°C. Then the slides were incubated with a 
monoclonal mouse anti-MMP-7 (RnD Systems) and a polyclonal goat anti-HB-EGF (Santa Cruz 
Biotechnology) antibody, respectively, in 3 % BSA/PBS for 1 h at 37°C. After washing with PBS, 
the slides were incubated for 1 h at 37°C with an AlexaFluor488-labeled chicken anti-goat 
antibody and a AlexaFluor568-labeled goat anti-mouse antibody (both Invitrogen), respectively. 
Control staining with the secondary antibodies alone revealed no detectable fluorescence. Co-
localization of MMP-7 and HB-EGF was investigated by a double staining for these proteins. 
Therefore, the anti-HB-EGF stained HMEC were fixed again, blocked with 10 % (v/v) goat 
serum and were subsequently incubated with monoclonal mouse anti-MMP-7 antibody and the 
appropriate secondary antibody. Following an additional washing step, further incubation was 
performed with the DNA-intercalating dye Hoechst 33258 (Invitrogen) for detection of the 
nuclei. After two final washing steps with PBS and ddH2O, the slides were mounted using 
ProLong Gold Antifade (Invitrogen). Epifluorescence microscopy was performed with a 
Keyence BZ-8100 using the appropriate Keyence software (Keyence).  
2.2.2.3 Immunofluorescence detection of fibrillin-1 and elastin 
For immunofluorescence detection of cell-associated elastin-like fiber formation, HMEC P16 
control populations and BAPN-treated HMEC P16 were fixed with 4 % paraformaldehyde for 
10 min at room temperature and processed as described above. The slides were incubated with a 
monoclonal mouse anti-fibrillin-1 antibody (Thermo Fisher Scientific) and an AlexaFluor488-
labeled goat anti-mouse antibody (Invitrogen). An additional blocking step with 10 % (v/v) 
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mouse serum for 1 h at 37°C was followed by the incubation with a monoclonal mouse anti-
elastin antibody (Santa Cruz Biotechnology) and an AlexaFluor568-labeled goat anti-mouse 
antibody (Invitrogen). Control staining with the secondary antibodies alone revealed no 
detectable fluorescence. Further incubation was performed with the DNA-intercalating dye 
Hoechst 33258 (Invitrogen) for detection of the nuclei. After two final washing steps with PBS 
and ddH2O, the slides were mounted using ProLong Gold Antifade (Invitrogen). 
Epifluorescence microscopy was performed with a Leica AF-6000 using the appropriate Leica 
LAS software (Leica). 
2.2.2.4 Immunofluorescence of extracellular matrix fibers 
For immunofluorescence of extracellular matrix, the extracellular filaments were harvested, plated 
on silanized slides (Dako) and fixed with 4 % (v/v) paraformaldehyde for 10 min at room 
temperature. For a better visualization of matrix proteins, the fibers were incubated with 6 M 
guanidine hydrochloride, 50 mM DTT in 20 mM Tris pH 8 for 15 min at room temperature. 
After careful washing with 20 mM Tris pH 8, an incubation in the dark followed with 100 mM 
iodacetamide in 20 mM Tris pH 8 for 15 min at room temperature to alkylate free sulfhydryl 
groups. An additional washing step with 20 mM Tris pH 8 is then followed by the incubation 
with 3 % BSA/PBS for 30 min at 37°C. Thereafter, the fibers were incubated with a monoclonal 
mouse anti-fibrillin-1 antibody for 1 h at 37°C. After washing with PBS, the slides were incubated 
for 1 h at 37°C with an AlexaFluor488-labeled goat anti-mouse antibody (Invitrogen). An 
additional blocking step with 10 % (v/v) mouse serum for 1 h at 37°C was followed by the 
incubation with a monoclonal mouse anti-elastin antibody (Santa Cruz Biotechnology) (1 h; 
37°C) and an AlexaFluor568-labeled goat anti-mouse antibody (Invitrogen) for 1 h at 37°C. After 
two final washing steps with PBS and ddH2O, the slides were mounted using ProLong Gold 
Antifade (Invitrogen). Epifluorescence microscopy was performed with a Leica AF-6000 using 
the appropriate Leica LAS software (Leica). Control staining with the secondary antibodies alone 
revealed no detectable fluorescence. 
 
2.2.3 Biochemical methods 
2.2.3.1 Protein quantification by BCA protein assay 
Protein quantification measurement was performed in microtiterplates using the BCA Protein 
Assay Reagent Kit according to the manufacturer’s recommendations (Pierce). The method 
combines the biuret reaction, known as the reduction of Cu2+ to Cu+ by protein in an alkaline 
medium, with the calorimetric detection based on the chelation of Cu+ by two bicinchoninic acid 
(BCA) molecules. The calibration curve was prepared with defined concentrations of bovine 
serum albumin (BSA, Pierce) and absorption was read at 562 nm using a Multiscan EX with the 
Ascent Software version 2.6 (Thermo Fisher Scientific). 
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2.2.3.2 Protein separation by SDS-polyacrylamide gel electrophoresis 
Glycine gel electrophoresis 
Glycine gel electrophoresis was performed according to the Laemmli protocol (Laemmli, 1970). 
Resolving and stacking gel demonstrate discontinuities in pH value and ionic strength. 
 
Loading buffer pH 6.8 (5x) 
Tris  
Glycine 
SDS  
DTT   
Bromphenol blue 
 
Resolving gel (10 %) 
ddH2O  
1.5 M Tris-Base  pH 8,8 
37.5 % Acrylamide (w/v)  
10 % SDS (w/v) 
10 % APS (w/v) 
TEMED 
 
Stacking gel (4 %)  
ddH2O 
0.5 M Tris/HCl  pH 6,8 
37.5 %  Acrylamide (w/v) 
10 %  SDS (w/v) 
10 %  APS (w/v) 
TEMED 
 
2.5 M 
40 %  (w/v) 
2.5 % (w/v) 
25 mM 
0.005 % (w/v) 
 
 
4.5 ml 
2.5 ml 
2.7 ml 
100 µl 
50 µl 
50 µl 
 
 
3 ml 
1.25 ml 
540 µl 
50 µl 
38 µl 
13 µl 
10x electrophoresis buffer 
Tris base  
Glycine  
SDS  
 
 
 
Resolving gel (7.5 %) 
ddH2O  
1.5 M Tris-Base  pH 8,8 
37.5 % Acrylamide (w/v)  
10 % SDS (w/v) 
10 % APS (w/v) 
TEMED 
 
0.25 M 
1.92 M 
1 % (w/v) 
 
 
 
 
5.2 ml 
2.5 ml 
2 ml 
100 µl 
50 µl 
50 µl 
  
 
Tricine gel electrophoresis 
For a better resolution of low molecular weight peptides and proteins, the tricine buffer system 
was used according to the Schagger protocol (Schagger, 2006). 
 
Loading buffer pH 6.8 (3x) 
Tris  
Glycine 
SDS  
DTT   
Bromphenol blue 
 
2.5 M 
40 % (w/v) 
2.5 % (w/v) 
25 mM 
0.005 % (w/v) 
Gel buffer pH 8.45 (3x)
Tris base  
SDS 
 
 
 
 
3 M 
0.3 % (w/v) 
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Resolving gel (10 %) 
3x Gel buffer pH 8.45 
37.5 % Acrylamide (w/v)  
Glycerol 
ad ddH2O 
10 % APS (w/v) 
TEMED 
 
Anode buffer pH 8.9 (10x) 
Tris base 
 
5 ml 
3 ml 
1.5 g 
ad 15 ml 
75 µl 
75 µl 
 
 
2 M 
Stacking gel (4 %)
3x Gel buffer pH 8.45 
37.5 % Acrylamide (w/v)  
ad ddH2O 
10 % APS (w/v) 
TEMED 
 
 
Cathode buffer (10x) 
Tris base 
Tricine 
SDS (w/v) 
 
1.5 ml 
0.5 ml 
ad 6 ml 
40 µl 
15 µl 
 
 
 
1 M 
1 M 
1 % 
 
Equal amounts of protein lysate were mixed with loading buffer pH 6.8, denatured at 95°C for 
5 min and cooled on ice before loading. The samples were separated using glycine- and tricine 
gels (10 % and 7.5 %), respectively, in the Mini-Protean 3 Electrophoresis Systems (BioRad), 
starting with 60 V for 30 min and increasing to 80 V for about 2 h until the bromphenol blue 
reached the lower end of the gel matrix. Standardization was performed using pre-stained low-
molecular-weight markers (BioRad).  
2.2.3.3 Coomassie stain of SDS-polyacrylamide gels 
Fixative Solution 
Ethanol  
Acetic acid 
 
40 % (v/v) 
10 % (v/v) 
 
Destain solution 
Methanol 
 
25 % (v/v) 
 
Stain solution
5x Roti Blue (Roth) 
Methanol 
 
20 % (v/v) 
20 % (v/v) 
 
 
For visualization of the separated proteins, the gels were stained with Coomassie brilliant blue 
after electrophoresis (2.2.3.2). The detection limit for Coomassie stain is about 200-400 ng 
protein. Proteins were fixed in the gel by incubation with fixative solution for 1h at room 
temperature followed by the incubation in staining solution for 12 h. Thereafter, the gel was 
washed several times with destain solution to reduce the background. 
The Coomassie-stained gels were shrink-wrapped in ddH2O and stored at 4°C. 
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2.2.3.4 Western blot: protein transfer on nitrocellulose membranes 
Transfer buffer 
Glycine 
Tris 
SDS 
Methanol 
39 mM 
48 mM 
1.2 mM 
20 % (v/v) 
 
After gel electrophoresis, the separated proteins were transferred to a nitrocellulose membrane 
(Hybond-C Extra, Amersham) using the tank blot systems TE 22 Mini and the TE 62 Tank 
Transfer Unit, respectively (Amersham). Therefore, both the gel as well as the nitrocellulose 
membrane were equilibrated in transfer buffer for 10 min. The sponge and the blotting paper 
were soaked in the buffer. All components were layered in the transfer cassette according to the 
transfer direction, placed in the chilled transfer tank and the proteins were blotted for 1-1.5 h at 
100 V. 
2.2.3.5 Immunoblot analysis 
PBST 
1x PBS  
0.05 % Tween 20 
 
Blocking buffers 
- 5 % FCS in 1x PBST 
- 5 % non-fat dry milk in 1x PBST 
Storage buffer
Glycerine 
Sodium acid 
87 % (w/v) 
0.02 % (w/v) 
 
After a successful protein transfer on the nitrocellulose membrane, unspecific binding was 
prevented by incubation with blocking buffer. Usually, 5 % FCS/PBST was used as blocking 
solution. However, for the detection of extracellular matrix proteins 5 % non-fat dry milk/PBST 
served as a better blocking reagent. Subsequently, the membranes were incubated with the 
distinct polyclonal or monoclonal primary antibodies for 2 h at room temperature or over night 
at 4°C, respectively, diluted in the particular blocking solution. Excessive antibody solution was 
removed by several washing steps with PBST. Following incubation with the appropriate 
peroxidase-conjugated secondary antibody for 1 h at room temperature and additional washing 
steps, the blots were developed using the ECL detection kit (Perkin Elmer) followed by exposure 
to a Hyperfilm (GE Healthcare). Eventually, the exposed film was developed in the X-ray 
Processor XP505 (3M). 
Afterwards, the membrane was shrink-wrapped with storage buffer and kept at 4°C. 
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2.2.3.6 Stripping: removal of the bound antibody complex from the membrane 
Stripping buffer pH 6.8 
Tris 
SDS 
DTT 
62.5 mM 
2 % (w/v) 
100 mM 
 
The membranes could be used for detection of further proteins. Therefore, the original bound 
antibody complex was removed from the membrane by shaking it in stripping buffer pH 6.8 for 
30 min in a 60°C-water bath. Subsequent washing in PBST removed the stripping solution and 
the membrane could be utilized in another immunoassay, starting with the blocking buffer 
(2.2.3.5). Subsequent incubation with a specific antibody allowed the detection of a distinct 
protein. 
2.2.3.7 Cervatec p16INK4a ELISA 
This assay was used for the quantitative determination of human p16INK4a protein in the different 
HMEC populations during cellular senescence and was performed according to the 
manufacturer’s recommendations (mtm laboratories). Briefly, 1 x 106 HMEC of passages 12 to 16 
were collected in the appropriate Cervatec sampling vial (mtm laboratories) and incubated in the 
associated heating block (mtm laboratories). After incubating the samples in the particular 
microtiter stripes, the absorbance was measured at 450 nm using the Multiskan Ascent FL with 
Ascent software version 2.6 (Thermo Fisher Scientific). 
2.2.3.8 Lysyl oxidase (LO) activity assay 
4x LO-buffer pH 8.2 
Urea 
Sodium borate 
4.8 M
200 mM 
 
Stock solutions  
Amplex red 
Horseradish peroxidase 
1,5-diaminopentane 
β-aminopropionitrile (BAPN) 
10 mM
1000 U/ml 
8.54 M 
50 mM 
 
The LO activity assay is based on an indirect fluorescent method described by Palamakumbura 
and Trackman (Palamakumbura and Trackman, 2002). LO activity was determined in 
conditioned cell culture media as well as in whole cell lysates of HMEC. Conditioned media of 
young HMEC P12 and senescent HMEC P16 were collected after a 72 h culture period and 
concentrated about 25-fold using Amicon Ultra-4 Centrifugal Filter Units with an Ultracel-10 
membrane (Millipore). Alternatively, HMEC P12 to P16 were harvested by trypsinization and 
Material and Methods 
 
45 
 
1x106 cells were homogenized in 4x LO-buffer pH 8.2. Both the concentrated media as well as 
the cell homogenates were subjected to a protein quantification measurement using the BCA 
protein assay (Pierce) (2.2.3.1).  
For the fluorescent-based LO activity assay, samples were prepared in a final volume of 2 ml, 
containing 1.2 M urea, 50 mM sodium borate (pH 8.2), 1 U/ml horseradish peroxidase, 10 mM 
1,5-diaminopentane (all from Sigma-Aldrich) and 10 µM Amplex red (Invitrogen). While LOs 
can oxidatively deaminate peptidyl lysine residues in vivo, these enzymes can also deaminate non-
peptidyl amines in vitro, and thus, previous work has demonstrated that the 1,5-diaminopentane 
provides an optimal enzyme substrate in this assay (Trackman et al., 1981). The amine oxidation 
is accompanied by the release of hydrogen peroxide, which in turn reacts with Amplex red in the 
presence of horseradish peroxidase in a 1:1 stoichiometry to form the fluorescent product 7-
hydroxy-3H-phenoxazine-3-one (resorufin).  
Inhibitor samples were similarly prepared, but additionally contained the specific LO-inhibitor β-
aminopropionitrile (BAPN) (500 µM) (Sigma-Aldrich) to completely abolish LO activity. The 
calibration curve was set up in the same buffer system using different amounts of hydrogen 
peroxide ranging from 0.025 ng to 1 ng. All samples were incubated for 1.5 h at 37°C. Finally, the 
fluorescent product was excited at 544 nm, and the emission was detected at 590 nm using the 
Fluoroskan Ascent FL with the appropriate Ascent software version 2.6 (Thermo Scientific). The 
resulting difference in fluorescence intensity between the control sample and the appropriate 
BAPN sample was recorded and normalized to the cell number. 
 
2.2.4 Statistical analysis 
All assays were performed in triplicate and experiments were repeated at least twice to confirm 
the results. Data represent mean ± SD and were statistically analyzed using the unpaired T-test 
(Microsoft Excel). Results were considered as statistically significant when P value was < 0.05 
(*P < 0.05; **P < 0.01; ***P < 0.001). 
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3 Results 
3.1 Cellular senescence in human mammary epithelial cells (HMEC) 
3.1.1 Proliferation and morphology of HMEC during long term culture 
Cellular senescence of primary HMEC is associated with significant morphological and functional 
changes. Young HMEC exhibited small, adherent cells which grew as a monolayer with frequent 
cell divisions (Figure 9a). But long term culture of these cells, and thus, the advanced senescence 
implicated considerable changes in cell morphology. The cells progressively increased in cell size 
and during passage 14 (P14) the enlarged HMEC formed long cytoplasmic processes spread 
across several neighbor cells. Finally, senescent HMEC after P16 developed enormous giant cells, 
exhibiting several fold the size of young P12 HMEC (Figure 9a). Consistent with the enlarged 
morphology of senescent HMEC, determination of the total protein amount in HMEC P12 
compared to HMEC P16 demonstrated a significant increase in the protein quantity per cell 
during cellular senescence (Figure 9b).  
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Figure 9: Morphological changes and the total protein amount per cell following senescence of 
HMEC.   
(a) The morphology of HMEC cultures in passage 12, 14 and 16 was visualized by Pappenheim-staining. The initially 
young small HMEC in P12 increased in size and grew up to giant cells in P16 (magnification 200x) (Bertram and 
Hass, 2008a). (b) The total amount of proteins per cell was determined in the different HMEC populations, revealing 
a progressive increase during cellular senescence. Data represent mean ± SD of three independent experiments. 
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Whereas young small HMEC until P13 possessed strong proliferative capacity, demonstrated by 
population doublings per day (Figure 10a), cell growth was gradually reduced with increasing 
culture period and advanced cellular senescence. While young HMEC P12 doubled 
approximately every 1.5 days, HMEC P14 had a doubling time of about 5 days and, finally, in 
senescent HMEC P16 little if any cell division could be detected (Figure 10a). However, this was 
not associated with an increase in cell death. Both the young proliferative HMEC populations 
and the senescent populations demonstrated a cell viability of about 92 % to 85 %, respectively 
(Figure 10b). Thus, senescent cells cease proliferation but remain in a viable and metabolically 
active state. 
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Figure 10: Analysis of proliferative capacity and cell viability in HMEC cultures. 
(a) Within the appropriate passages, cell number and cell viability were determined by trypan exclusion. Proliferative 
capacity, represented by population doublings per day, significantly decreased during cellular senescence of HMEC. 
Error bars represent the mean ± SD of five independent experiments. (b) However, cell viability was not affected by 
the aging process and both young and senescent HMEC demonstrated about 92 % to 85 % viable cells. Error bars 
represent the mean ± SD of five independent experiments. (Bertram and Hass, 2008a)  
 
3.1.2 HMEC cell cycle distribution during cellular senescence 
As exemplified by the proliferation data (Figure 10), cellular senescence of HMEC was 
accompanied by a remarkable decrease in cell growth. This was substantiated by flow cytometry 
analysis of the cell cycle distribution in HMEC populations between passage 12 and 16 (Figure 
11). Cell cycle histograms exemplarily represented the cell cycle pattern of HMEC P12, P14 and 
P16, respectively (Figure 11a) and quantitative evaluation of the distinct cell cycle phases is 
shown in the bar diagram (Figure 11b). With increasing culture period, cell cycle analysis of the 
different stages during senescence revealed a continuously decreasing amount of cells with 
2N DNA (from 73 % ± 1.1 % in P12 to 32 % ± 1.0 % in P16) and S phase cells (from 
7 % ± 0.3 % in P12 to 2 % ± 0.2 % in P16), respectively. On the contrary, markedly elevated 
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levels could be detected for the 4N DNA population with progressing senescence (from 
17 % ± 0.5 % in P12 to 44 % ± 0.5 % in P16). Moreover, this was paralleled by the appearance 
of a peak in the range of 8N DNA, probably representing aberrant mitosis with DNA doubling 
but no subsequent cell division. In conformity with the viability data, no massive cell death could 
be discovered by flow cytometry during cellular senescence of HMEC and the amount of dying 
cells indicated by the degraded DNA remained below 5 % (Figure 11b). These findings suggested 
senescence to be initiated following passage 13 and finalized after passage 15.  
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Figure 11: Cell cycle analysis of HMEC cultures during cellular senescence. 
(a) The cell cycle distribution of HMEC P12, P14 and P16 is represented by flow cytometric histograms and (b) 
quantitative determination of each particular cell cycle phase was evaluated using FlowMax software. A progressively 
decreasing level of cells with 2N DNA was paralleled by an accumulation of 4N DNA cells during the aging process 
of HMEC. HMEC populations after P15 ceased to divide. Following aberrant mitosis by DNA doubling without cell 
division a population with 8N DNA arose. Data represent mean ± SD of three independent experiments. (Bertram 
and Hass, 2008a) 
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3.1.3 Senescence-associated marker proteins 
To further characterize the senescent status of the different HMEC populations, expression and 
activity of distinct senescence-associated proteins was investigated. It was previously 
demonstrated that the activity of the enzyme senescence-associated β-galactosidase (SA β-gal) 
markedly increased in certain senescent cells, including HMEC (Romanov et al., 2001). 
Determination of SA β-gal activity was performed using a cytological assay which allows the 
visualization of substrate turnover. The synthetic substrate X-gal, composed of a galactoside 
linked to indole, is cleaved by SA β-gal and subsequent oxidation results in the development of a 
blue color. Images of the cytological staining of young and senescent HMEC are exemplarily 
shown in passage 12, 14 and 16 demonstrating the missing activity in HMEC P12 in contrast to 
the high SA β-gal activity and the predominant staining in HMEC P16 (Figure 12a). 
Quantification revealed only 6 ± 1.4 % positive cells in the HMEC P12 population, whereas the 
amount of SA β-gal-active cells gradually increased with succeeding culture period and the P16 
cell population demonstrated SA β-gal activity in 81 ± 2.5 % of the cells (Figure 12b). 
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Figure 12: SA β-gal activity in HMEC 
during cellular senescence. 
(a) Phase contrast images displayed strong SA β-gal 
enzyme activity by green colored cells in senescent 
HMEC P16 in contrast to the marginal color in 
HMEC P12 (magnification 200x).  
(b) Quantification revealed about 6 % SA β-gal 
positive cells in HMEC P12. Subsequently, SA β-gal 
active cells progressively increased with a maximum 
of about 80 % in HMEC P16. Error bars represent 
the mean ± SD of three independent experiments. 
(Bertram and Hass, 2008a)  
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Figure 13: Expression of the cell cycle inhibitor p16INK4a in HMEC. 
(a) Cytological staining of HMEC P12 and P16 revealed no p16INK4a protein expression in either HMEC passage. 
Primary breast epithelial cultures, obtained from a surgery, were used as a positive control and the p16INK4a 
expression could be monitored by a brown staining in the enlarged, cell cycle-arrested cells. Cell nuclei were 
visualized by Haematoxylin staining (magnification 200x). (b) Quantitative determination of p16INK4a protein by 
ELISA confirmed p16INK4a levels below detection limit (Co low) in all HMEC populations. Accordingly, this 
characterizes the post-selection state of these HMEC populations (Huschtscha et al., 1998). Data represent the mean 
± SD of three independent experiments. 
 
However, an increased SA β-gal activity on its own cannot be accepted to prove senescence and 
requires additional verification. Thus, the senescent state of HMEC was further examined by 
expression analysis of the cell cycle inhibitor p16INK4a. The growth phase of HMEC can be 
distinguished by discrete proliferation barriers, named stasis and agonescence. Whereas stasis is 
characterized by a significantly increasing expression of the cell cycle inhibitor p16INK4a, HMEC 
overcoming this barrier by a selection process lack the expression of this CDK inhibitor. The 
expression status of p16INK4a in HMEC was detected by a cytological immunostaining, 
demonstrating the presence of p16INK4a by a brown color (Figure 13a). The cell nuclei were 
counterstained with Haematoxylin and primary breast epithelial cells, obtained from a surgery, 
were used as a positive control. Whereas in enlarged cell cycle-arrested control cells a strong 
brown color was exhibited, expression of the cell cycle inhibitor was not detectable in the small 
Results 
 
51 
 
dividing control population (Figure 13a, control). Cytological immunostaining of cultured HMEC 
between P12 and P16, however, revealed no detectable p16INK4a expression in either population 
(Figure 13a, HMEC P12 and HMEC P16). This was further substantiated using quantitative 
determination of p16INK4a protein expression by ELISA (Figure 13b). Control samples provided 
with the ELISA kit established the concentration range for low p16INK4a protein levels (Co low) 
and for high p16INK4a quantity (Co high) (Figure 13b). However, independent of their proliferative 
capacity and their aging state, all HMEC populations displayed a p16INK4a protein amount below 
the lowest control level (Figure 13b), validating the qualitative results from the cytological 
immunostaining (Figure 13a).  
In conclusion, these results (3.1.1-3.1.3) allowed the characterization of HMEC P12 as young, 
proliferative post-selection HMEC and cells in P16 as senescent, cell cycle-arrested post-selection 
HMEC. In the following, every HMEC culture described and each experiment performed is 
always referred to post-selection HMEC, which finally encounter telomere-dependent 
agonescence. 
 
3.2 Alterations of extracellular-associated proteins during cellular senescence of 
HMEC 
Changes of proliferative capacity, cell morphology and cell attachment processes in senescent 
HMEC suggested further functional alterations correlated with the aging process of these cells. 
Initially, investigations were focused on molecules involved in cell-cell and cell-matrix 
interactions such as cell surface glycoproteins and certain matrix metalloproteinases (MMPs). 
 
3.2.1 Cell surface proteins 
Accordingly, a variety of surface adhesion molecules were examined during cellular senescence of 
HMEC and the human breast carcinoma cell line MCF-7 was used as a reference. Preferred cell 
surface proteins were represented by CD24, CD29, CD44 and CD227 (MUC1). Whereas the β1-
integrin family member CD29 was uniformly expressed in the cancer cell line as well as in young 
and senescent post-selection HMEC at about 100 %, expression levels of CD24 and CD44 were 
affected by the aging process of HMEC (Figure 14). The detected fluorescence intensity of nearly 
100 % for CD24 and CD44 was similar in young HMEC and the immortalized MCF-7 cell line 
but was significantly reduced to 66 % and 61 % in senescent HMEC, respectively (Figure 14). 
CD227 protein levels, however, were already decreased when comparing primary HMEC P12 
(81 %) with the MCF-7 tumor cell line (97 %) and further declined upon senescence (40 %) 
(Figure 14). Previous work has demonstrated alterations of certain protein levels upon long-term 
culture of MCF-7 (> P500) such as a loss of transforming growth factor-beta type II receptor 
(Wu et al., 1998; Wenger et al., 2004) or distinct surface proteins (Hand et al., 1983). The short-
term passages of MCF-7 cells we used in our lab (P <150), however, demonstrated no alterations 
in surface marker expression caused by subculturing (data not shown). 
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Figure 14: Analysis of cell surface proteins in HMEC and tumorigenic MCF-7 cells. 
The β1 integrin family member CD29 was uniformly expressed during the aging process of HMEC. However, CD24, 
CD44 as well as CD227 were significantly down-regulated in association with HMEC senescence. In contrast, 
tumorigenic MCF-7 exhibited these surface markers at about 100 %. Data represent the mean ± SD of three 
independent experiments. (Bertram and Hass, 2008a) 
 
3.2.2 Matrix metalloproteinases (MMPs) 
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Figure 15: Expression analysis of MMPs during senescence of HMEC. 
Both the latent progenitor form and the proteolytically active form of MMP-1, MMP-2 and MMP-9 were uniformly 
expressed in all passages of aging HMEC. However, the latent form of MMP-7 was slightly decreased after P15 and 
the active enzyme diminished below detection level in P16. The cytoskeletal protein β-actin was used as loading 
control. (Bertram and Hass, 2008a) 
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Matrix metalloproteinases comprise a strong proteolytic activity and thus are involved in ECM 
degradation and remodeling as well as modification of signaling molecules and activation of 
precursor proteins. Therefore, it was of interest to examine the expression pattern of certain 
MMPs during the process of cellular senescence in HMEC. Each MMP can be distinguished into 
its latent precursor form and its cleaved, active form, respectively. Thus, MMP-1, MMP-2 and 
MMP-9 demonstrated equal expression levels between P12 and P16 for both the latent and active 
form of these proteins and were not influenced by HMEC senescence (Figure 15). In contrast, 
latent MMP-7 exhibited a slight down-regulation between passage 15 and 16, which was even 
more pronounced by the active form. Active MMP-7 was significantly reduced after P14 and the 
protein quantity was below detection level in P16 (Figure 15), indicating a potential role of this 
extracellular protease during cellular senescence of HMEC. 
 
3.3 The role of MMP-7 during cellular senescence of HMEC 
In order to investigate a possible role of MMP-7 in the context of HMEC senescence, its 
expression was targeted by RNAi in HMEC P12. Accordingly, reduced MMP-7 protein levels in 
young HMEC induced by siRNA targeting could reveal potential implications of an impaired 
MMP-7 signaling associated with the HMEC senescence process. 
 
3.3.1 Down-modulation of MMP-7 induced a premature senescence in young HMEC 
Primary HMEC in passage 12 were initially transfected with pmaxGFP plasmid to verify the 
transfection method using the Nucleofector (amaxa). Thus, different manufacturer-
recommended programs were tested and GFP expression was examined by fluorescence 
microscopy (data not shown). The program, resulting in the best balance between cell viability 
and transfection efficiency, represented by GFP expression (Figure 16a), was used for further 
transfection experiments. Additionally, non-silencing, green fluorescence-labeled siRNA-AF488 
(FITC-siRNA) was used to analyze the transfection efficiency, when comparing FITC-labeled 
siRNA transfected HMEC with non-transfected HMEC by flow cytometry. This demonstrated 
about 80 % transfected cells using the nucleofector program X-005 (Figure 16b). Down-
modulation of MMP-7 was performed by transfection of young HMEC P12 with two specific 
MMP-7 siRNAs and the appropriate control transfections were carried out using non-targeting 
AllStars Negative Control siRNA (neg. siRNA) (2.1.4 and 2.2.1.12). Following incubation for 
24 h, 48 h and 72 h, respectively, the cells were harvested and MMP-7 protein levels were 
documented by Western blot analysis (Figure 16c). This demonstrated a significant down-
modulation of both the latent and the active form of MMP-7 between 48 h and 72 h in contrast 
to unregulated protein levels in negative siRNA transfected HMEC, 24 h MMP-7 siRNA 
transfectants and pmaxGFP control transfectants (Figure 16c).  
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Figure 16: RNAi of MMP-7 in HMEC P12. 
(a) HMEC (HMEC control) and HMEC transfected with green fluorescence-labeled siRNA-AF488 (FITC-siRNA-
transfected HMEC) were analyzed by flow cytometry. The siRNA transfection using program X-005 of the 
Nucleofector II yielded in an efficiency of 80 %. (b) The pmaxGFP plasmid was provided with the HMEC 
nucleofector kit and served as a positive control. 48 h post transfection, pmaxGFP-transfected cells were visualized 
by phase contrast and fluorescence microscopy, respectively. (c) HMEC transfected with MMP-7 siRNA were 
harvested 24 h, 48 h and 72 h post transfection and Western blot analysis revealed a significant down-modulation of 
both the latent and active form of MMP-7 after 48 h and 72 h compared to control-transfected HMEC. Staining 
with anti-β-actin was used as a loading control. (Bertram and Hass, 2008a) 
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Figure 17: Functional analysis of young HMEC after 
down-modulation of MMP-7. 
(a) Flow cytometry analysis revealed a cell cycle distribution of 
HMEC control cells, negative siRNA-transfected HMEC and 
24 h MMP-7 siRNA transfectants similar to HMEC P12. 
However, after 72 h, the amount of 2N DNA cells decreased 
in MMP-7 siRNA-transfected HMEC (48 %). This was 
paralleled by a marked accumulation of cells with 4N DNA 
(26 %), resembling a cell cycle pattern of HMEC populations 
in about P14 before reaching senescence in P16. Deviations 
from a total of 100 % result due to mathematical rounding and 
cells excluded from the gating regions as they represent no 
numeral DNA content. (b) Determination of SA β-gal activity 
revealed an increased amount of senescent cells in 72 h MMP-
7 siRNA transfectants (25 % ± 3.2 %) (**P < 0.005) compared 
to a 72 h populations of control HMEC (6 % ± 2.1 %) and 
negative siRNA transfectants (10 % ± 2.2 %), respectively. 
(Bertram and Hass, 2008a) 
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Subsequent functional investigations were performed by cell cycle analysis and SA β-gal assay to 
reveal potential effects on proliferation and senescence due to MMP-7 down-modulation in 
young HMEC. Flow cytometry analysis demonstrated a cell cycle distribution of negative siRNA 
transfected HMEC resembling the pattern of non-transfected control cells in passage 12 (Figure 
17a), confirming that the transfection methods itself had no effect on the cell cycle. Moreover, 
24 h MMP-7 siRNA transfected cells displayed a similar cell cycle as the control populations. 
However, down-modulation of MMP-7 for 72 h induced significant alterations of the cell cycle 
pattern in these cells. Whereas the amount of cells with 2N DNA was markedly reduced (from 
60 % to 48 %), the 4N DNA population obviously increased from 18 % to 26 % (Figure 17a), 
suggesting an induced growth arrest upon decreased MMP-7 protein levels. When comparing the 
cell cycle distribution after MMP-7 RNAi with the different cell cycle patterns during cellular 
senescence, it became apparent that MMP-7 down-modulation provoked a cell cycle resembling 
that of aging HMEC in P14 before encountering senescence in P16 (Figure 17a). 
These findings were further verified by staining for SA β-gal activity (Figure 17b). Thus, SA β-gal 
activity was significantly increased after MMP-7 RNAi and revealed 25 % ± 3.2 % senescent cells 
in the 72 h MMP-7 siRNA transfected HMEC population in contrast to 6 % ± 2.1 % and 
10 % ± 2.2 % in 72 h non-transfected HMEC and negative siRNA transfectants, respectively 
(Figure 17b). These findings confirmed a premature senescence in HMEC P12 upon down-
modulation of MMP-7.  
Taken together, these results validated an important role of MMP-7 during cellular senescence of 
HMEC and demonstrated an accelerated aging process in young HMEC due to reduced protein 
levels of MMP-7. 
 
3.3.2 MMP-7 RNAi in the breast cancer cell line MCF-7 
The induced aging process as a consequence of down-modulated MMP-7 in primary normal 
HMEC was additionally evaluated in the breast cancer cell line MCF-7. Therefore, these 
immortalized cancer cells were transfected with MMP-7 siRNA and subsequently analyzed for 
alterations in MMP-7 protein expression, cell cycle distribution and SA β-gal activity (Figure 18). 
Successful down-modulation of MMP-7 was demonstrated for the latent precursor form as well 
as for the active protein form by Western blot analysis (Figure 18a). Cell cycle analysis of 
transfected MCF-7 cancer cells exhibited a slight increase of 2N DNA cells, whereas the amount 
of cells with 4N DNA decreased upon MMP-7 down-modulation (Figure 18b). Additionally, 
SA β-gal activity was slightly affected and increased upon MMP-7 siRNA transfection (Figure 
18c). However, compared to negative siRNA transfected HMEC, statistical analysis showed no 
significance of these values, suggesting that genetic alterations in this artificial, immortalized cell 
line may interfere with a sufficient induction of senescence.  
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Figure 18: MMP-7 down-modulation in MCF-7. 
MCF-7 breast cancer cells were transiently transfected with MMP-7 siRNA as compared to control cells and to 
negative siRNA transfected cells and harvested 48h post transfection. (a) Western blot analysis revealed a successful 
down-modulation of both the latent and active form of MMP-7 in the appropriately transfected MCF-7 population, 
whereby β-actin was used as loading control. (b) However, cell cycle distribution was not significantly affected by 
MMP-7 RNAi. Deviations from a total of 100 % result due to mathematical rounding and cells excluded from the 
gating regions as they represent no numeral DNA content. (c) The SA β-gal staining was increased in the MMP-7-
transfected MCF-7 population, but the unpaired t-test revealed no statistical significance. Data represent mean ± SD 
of three independent experiments. 
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3.4 The role of the extracellular matrix (ECM) during cellular senescence of 
HMEC 
3.4.1 The extracellular filaments 
Cellular senescence of HMEC was associated with an enhanced formation of extracellular 
filaments. A stable network of fine characteristic structures became detectable in HMEC cultures 
after passage 14 and markedly increased in the senescent P16 population (Figure 19). These 
regular, well-organized fine fibers spread across the media surface of senescent HMEC, whereas 
no comparable structures were observed in HMEC between P12 and P14.  
Immunofluorescence analysis of this extracellular filament allowed the detection of certain matrix 
proteins as compounds of these fibers, including fibrillin-1 and polymeric elastin (Figure 20). 
Immunostaining with a specific anti-elastin antibody revealed a fibrillar organization of this 
polymer, whereas the anti-fibrillin-1 antibody recognized a scattered pattern of structures with 
distinct localization (Figure 20). The merged fluorescence images demonstrated that these 
distinctive appearing fibrillin-1 structures co-localize with the fibrillar shape of elastin, suggesting 
the extracellular filament in senescent HMEC cultures to be composed of elastin-like structures. 
Control experiments confirmed the specificity of the secondary antibodies and immunostaining 
with these antibodies alone revealed no detectable fluorescence. 
 
 
100x 200x
 
 
Figure 19: Extracellular fiber network in senescent HMEC cultures. 
Phase contrast images showed a regular, well-organized network of distinct fibers in the senescent HMEC culture 
(magnification 100x and 200x). However, no comparable structures were visible in cultures of young, dividing 
HMEC in P12 to P14. 
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Figure 20: IF analysis of the extracellular filament in senescent HMEC cultures. 
Immunofluorescence allowed the detection of the ECM proteins fibrillin-1 and polymeric elastin. While the anti-
elastin antibody identified a fibrous network (red), the anti-fibrillin-1 antibody demonstrated a distinctive scattered 
pattern (green). The merged image showed an overlay of elastin with fibrillin-1, suggesting a filament composed of 
elastin-like structures in the senescent HMEC population (bar = 30 µm).  
 
3.4.2 Fiber maturation during HMEC senescence is BAPN-dependent 
Elastin fiber generation requires enzyme activity of lysyl oxidases (LOs). This enzyme family is 
responsible for cross-linking of the elastin precursor protein tropoelastin to form insoluble elastic 
filaments as part of the ECM (1.3.1.3). In order to verify the immunofluorescence detection of 
extracellular elastin in senescent HMEC cultures and to confirm the cellular origin of these 
elastin-like structures, LO activity was prevented by incubation with the synthetic LO inhibitor β-
aminopropionitrile (BAPN). HMEC populations were cultured in the presence and absence of 
BAPN for 12 days with regular media changes (2.2.1.3). Whereas the untreated HMEC P16 
populations generated elastin-like structures, no comparable extracellular fibers were detectable in 
HMEC P16 after BAPN incubation. Using immunofluorescence analysis, the anti-fibrillin-1 
antibody revealed small aggregates at the cell surface of HMEC populations independent of 
BAPN treatment (Figure 21). In contrast, the anti-elastin antibody detected cell-associated 
aggregates at the HMEC controls, whereas little if any elastin could be detected after BAPN 
stimulation (Figure 21). Moreover, the merged fluorescence images displayed a co-localization of 
fibrillin-1 and elastin in the HMEC P16 control populations in cell-associated aggregates and 
fibers. These data demonstrated that the elastin-like fiber formation in senescent HMEC P16 was 
inhibited upon BAPN incubation and thus is dependent on LO activity.  
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Figure 21: Cell-associated elastin-like fiber formation. 
Immunofluorescence studies of senescent control HMEC P16 compared to senescent BAPN-treated HMEC P16 
revealed the formation of cell-associated aggregates, consisting of elastin (red) and fibrillin-1 (green), at the cell 
surface of untreated HMEC populations. Moreover, the polymerization of extracellular elastin-like fibers could be 
observed in the controls. The BAPN-treated HMEC cultures demonstrated some cell-associated fibrillin-1; however, 
no elastin was detectable in these populations. The nuclei were stained using Hoechst 33258 (bar = 50 µm). 
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3.4.3 Lysyl oxidase expression and activity during cellular senescence of HMEC 
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Figure 22: LO protein expression and enzyme activity during cellular senescence of HMEC. 
(a) Protein expression of LOXL1, an important enzyme for cross-linking of elastin molecules, was gradually elevated 
during HMEC senescence and LOX demonstrated an increased expression in HMEC P16. (b) Enzyme activity 
measurements revealed a dramatic increase in extracellular LO activity in the conditioned media of senescent HMEC 
cultures P16 compared to the respective media of young HMEC P12 (***P < 0.0005). (c) Enzyme activity of cell-
associated LO was determined in HMEC lysates, demonstrating a progressive increase during cellular senescence 
(P12 to P16). Comparing young, dividing HMEC P12 and senescent HMEC P16, LO activity was 2.5-fold elevated 
in the senescent population (**P < 0.005) when calculated based upon an equal amount of cells. This was in concert 
with the measurements in the conditioned media. Data represent mean ± SD of three independent experiments.   
 
Subsequently, the question arose, whether this enhanced formation of extracellular structures in 
senescent HMEC cultures is accompanied by elevated LO protein levels and enhanced enzyme 
activities. Initially, intracellular expression levels of two distinct members of the LO enzyme 
family, LOX and LOXL1, were investigated during HMEC senescence, whereby LOXL1 is the 
enzyme predominantly involved in elastin polymerization. Expression of LOX was slightly 
affected by the aging process of HMEC and the protein levels were enhanced in passage 16 
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(Figure 22a). LOXL1 protein levels gradually increased after passage 13 and were significantly 
elevated in senescent HMEC P16 (Figure 22a).  
Although these results implied a marked increase in lysyl oxidase occurrence, these enzymes 
require proteolytic activation, and thus, it remained unclear if senescence is actually associated 
with an enhanced LO activity. To address this question, enzyme activity was determined by 
substrate turnover and subsequent detection of fluorescence intensity (Figure 22b and c). While 
LO can oxidatively deaminate peptidyl lysine residues in vivo, these enzymes can also deaminate 
non-peptidyl amines in vitro, and thus, previous work has demonstrated that the 1,5-
diaminopentane provides an optimal enzyme substrate in this assay (cp. 2.2.3.8) (Trackman et al., 
1981). Moreover, the amine oxidation is accompanied by release of hydrogen peroxide, which in 
turn reacts with N-acetyl-3,7-dihydroxyphenoxazine (Amplex red) in the presence of horseradish 
peroxidase in a 1:1 stoichiometry to the fluorescent product 7-hydroxy-3H-phenoxazine-3-one 
(resorufin). To exclude other oxidase activities and ensure exclusive determination of lysyl 
oxidase activity, samples were additionally prepared while adding of LO inhibitor BAPN. The 
resulting difference in fluorescence intensity, and thus, substrate turnover, finally provides the 
particular LO enzyme activity. During cellular senescence of HMEC, LO activity was determined 
in the extracellular environment (Figure 22b) as well as cell-associated (Figure 22c). Extracellular 
activity of secreted LO was examined in the 72 h cell culture supernatant of young proliferating 
HMEC P12 and compared to senescent HMEC P16, respectively. Thus, the conditioned media 
of senescent P16 cells revealed a more than 6-fold higher LO activity (***P < 0.0005) as 
compared to young proliferating P12 HMEC (Figure 22b). Moreover, cellular-associated LO 
activity in HMEC whole cell lysates was measured during senescence and demonstrated an about 
2.5-fold increased LO activity between P12 and P16 (*P < 0.005), when calculated based upon an 
equal amount of P12 and P16 cells (Figure 22c).  
Together, the increased formation of elastin-like structures in senescent HMEC cultures was 
accompanied by an elevated LOX and LOXL1 protein expression which was paralleled by a 
significantly enhanced cellular-associated and extracellular LO enzyme activity. 
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3.5 Extracellular MMP-7 is linked to intracellular signal transduction pathways 
The phenotypic alterations of the extracellular microenvironment in senescent HMEC 
populations, characterized by an increased maturation of elastin-like fibers, were substantiated by 
investigations at the post-translational level, including LO activity measurements and BAPN-
dependence. However, little is known about regulation of the elastin precursor protein 
tropoelastin during senescence, which is required for the generation of elastic fibers. Thus, 
besides tropoelastin expression analysis, a potential link to the decreased MMP-7 levels during 
HMEC senescence was examined. 
 
3.5.1 Expression pattern of tropoelastin during cellular senescence of HMEC 
Tropoelastin protein levels were analyzed in whole cell lysates of different HMEC populations 
between P12 and P16 by Western blot. The expression data demonstrated an elevated 
intracellular production of the elastin precursor during HMEC senescence (Figure 23). Cell-
associated human tropoelastin monomers increased in HMEC P14 and displayed maximal 
expression in P16 (Figure 23). As tropoelastin molecules covalently dimerize, a similar 
upregulation was observed for those dimers at an approximate molecular weight of 144 kDa 
(Figure 23). Remarkably, these data revealed inverse intracellular expression patterns for 
tropoelastin and the proteinase MMP-7 (cp. Figure 15 and Figure 23).  
MMP-7 is known to be responsible for ectodomain shedding of numerous cytokines and growth 
factors (1.3.3.4). In this context, other work identified a membrane-anchored complex of MMP-7 
with the heparin-binding epidermal growth factor-like growth factor (HB-EGF) to generate its 
soluble form sHB-EGF (Yu et al., 2002; Cheng et al., 2007; Lynch et al., 2007). Interestingly, 
expression of HB-EGF was detectable in young HMEC P12, but declined during senescence 
(Figure 23). Thus, the growth factor HB-EGF exhibited a similar protein regulation as MMP-7 
during cellular senescence of HMEC, suggesting potential signaling correlations. In this context, 
downstream signal transduction by sHB-EGF involves the transcription factor Fra-1, which 
among others triggers regulation of tropoelastin expression. Immunoblot analysis demonstrated 
that Fra-1 was markedly expressed in young HMEC P12 and P13, whereas the protein levels 
gradually decreased with continuous passage number and were, eventually, significantly 
diminished in the senescent P16 populations (Figure 23).  
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Figure 23: Expression of tropoelastin, HB-EGF and Fra-1 during cellular senescence of HMEC. 
Western blot analysis of whole cell lysates during cellular senescence of HMEC demonstrated an increasing 
expression of both the monomeric as well as the dimeric form of the elastin precursor protein tropoelastin in HMEC 
after passage 13. This was paralleled by a down-regulation of HB-EGF. The transcription factor Fra-1 was previously 
shown to be involved in intracellular HB-EGF-mediated tropoelastin regulation and decreasing Fra-1 protein levels 
were observed during cellular senescence of HMEC. An equal loading control was performed using an anti-β-actin 
antibody. 
 
 
3.5.2 Down-regulation of MMP-7 induced tropoelastin expression 
Besides the direct effect of MMP-7 on the degradation and remodeling of ECM, the inverse 
expression pattern between MMP-7 and tropoelastin during HMEC senescence may indicate a 
possible relationship of MMP-7 to processing signaling molecules and modifying downstream 
signals. In addition to the induction of an accelerated aging of HMEC by MMP-7 down-
regulation (see 3.3.1), the question arose, whether the decreased MMP-7 expression affects 
tropoelastin synthesis.  
According to paragraph 3.3.1, young proliferating HMEC P12 were targeted by a MMP-7 RNAi 
approach and reduced MMP-7 protein levels were investigated in the context of potential effects 
on tropoelastin expression (Figure 24). As already elucidated in detail above, control transfections 
were performed with pmaxGFP plasmid and transfection with non-silencing, green fluorescence-
labeled siRNA-AF488 revealed a transfection efficiency of approximately 75 %. In order to 
examine effects on downstream signaling pathways, MMP-7 down-regulation by RNAi was 
prolonged for 96 h. Thus, 48 h-transfected HMEC were harvested by trypsinization, submitted to 
a second siRNA transfection and incubated for another 48 h. 
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Figure 24: MMP-7 down-modulation affected tropoelastin expression. 
Young HMEC P12 were transfected with MMP-7 siRNA and harvested 48 h, 72 h and 96 h post transfection. 
Western blot analysis revealed a successful down-modulation of both the latent and active form of MMP-7 in MMP-
7 siRNA transfectants compared to control-transfected HMEC. The expression of tropoelastin was significantly 
affected by MMP-7 down-modulation. Reduced MMP-7 levels implicated about 1.5-fold elevated tropoelastin levels 
for both the monomer and the dimer of this protein in 96 h-MMP-7 siRNA transfected HMEC. Concerning 
potential signaling mechanisms, Fra-1 demonstrated a significant down-regulation in the MMP-7 RNAi transfectants 
after 48 h, which was maintained until 96 h post transfection. Normalization to β-actin protein levels was performed 
by densitometry and is indicated by arbitrary units in the y-axis (ImageJ). 
 
Finally, whole cell lysates were separated by SDS-gel electrophoresis and immunoblot detection 
revealed a successful down-modulation of both latent and active form of MMP-7 in MMP-7 
siRNA transfected HMEC as compared to non-transfected and negative siRNA-transfected 
controls (Figure 24). Normalization to β-actin protein levels by densitometry (ImageJ) confirmed 
these results. In contrast, MMP-7 down-modulation was accompanied by increasing expression 
of the elastin precursor protein tropoelastin. The monomeric form as well as the dimer displayed 
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about 1.5-fold elevated protein levels in MMP-7 siRNA-transfected HMEC after 96 h, when 
compared to negative siRNA transfectants (Figure 24). Following the initial hypothesis of an 
induced downstream signaling by MMP-7, including the transcription factor Fra-1, expression 
analysis revealed Fra-1 levels after 96 h-MMP-7 siRNA transfection to be reduced to about one 
third of the protein levels in the control populations (Figure 24).  
Taken together, these data confirmed a direct link between MMP-7 down-regulation and an 
increased tropoelastin expression during cellular senescence of HMEC. Although the associated 
intracellular pathways that trigger an up-regulation of tropoelastin expression during HMEC 
senescence still remain unclear, HB-EGF signaling via Fra-1 could represent one possible piece 
in this puzzle. 
 
3.5.3 MMP-7 affected HB-EGF signaling via Fra-1  
In order to follow a possible role of HB-EGF-transduced signaling in the regulation of 
tropoelastin expression during HMEC senescence, HB-EGF was down-modulated by RNAi in 
HMEC P12. Subsequently, potential effects of an impaired HB-EGF expression in young 
HMEC were evaluated on cell growth and expression of affected signaling molecules. Moreover, 
LO enzyme activity measurements could verify further processing of a potentially induced 
tropoelastin amount. 
Control experiments for successful transfection and transfection efficiency were performed as 
described above (3.3.1) and revealed similar results as indicated for MMP-7 RNAi (Figure 16). 
Suppression of HB-EGF mRNA translation by siRNA was maintained for 96 h by a second 
siRNA transfection after 48 h as indicated for MMP-7 RNAi (3.5.2). This ensured sufficient 
prevention of HB-EGF biosynthesis to allow investigation of interacting downstream signaling 
molecules. HB-EGF expression analysis demonstrated a successful down-modulation in HB-
EGF siRNA transfected HMEC as compared to the non-transfected and negative siRNA 
transfected controls (Figure 25a). Similarly, Fra-1 protein was down-regulated in HB-EGF RNAi 
transfectants (Figure 25a). However, both tropoelastin monomers as well as tropoelastin dimers 
revealed enhanced protein levels in the HB-EGF RNAi transfectants (Figure 25a).  
Functional studies of the transfectants by cell cycle analysis revealed a significant amount of cell 
death in HB-EGF siRNA-transfected HMEC as compared to the control cell groups 
(***P < 0.0005 and **P < 0.01, respectively), indicated by cell populations with degraded DNA 
(Figure 25b). Moreover, aberrant mitosis, as documented by the accumulation of cells with 8N 
DNA, was markedly elevated in 96 h-HB-EGF siRNA transfected HMEC in contrast to non-
transfected (*P < 0.05) and negative siRNA transfected control cells (*P < 0.05) (Figure 25b).  
Moreover, it was investigated if excessive tropoelastin levels due to HB-EGF down-modulation 
might interfere with extracellular LO enzyme activity. Indeed, cross-linking activity of lysyl 
oxidases considerably differed from the control transfected HMEC and was significantly elevated 
after HB-EGF down-modulation (*P < 0.05) (Figure 25c).  
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Figure 25: RNAi of HB-EGF in HMEC P12. 
(a) HMEC P12 were transfected with HB-EGF siRNA and harvested 96 h post transfection. Western blot analysis 
revealed a successful down-modulation of HB-EGF protein levels in HB-EGF siRNA transfected HMEC compared 
to non-transfected and negative siRNA transfected cells. In addition, transcription factor Fra-1 protein levels were 
reduced in HB-EGF siRNA targeted HMEC. HB-EGF and Fra-1 down-modulation were paralleled by an increase 
in tropoelastin expression and both the tropoelastin monomer and dimer were elevated in HB-EGF RNAi HMEC. 
(b) The cell cycle distribution was evaluated in HMEC transfected with HB-EGF siRNA, non-transfected HMEC 
and negative siRNA-transfected cells. After 96 h, HB-EGF down-modulation was associated with a dramatic 
increase in cell death. The amount of apoptotic cells increased more than 2.5-fold compared to negative siRNA 
transfectants (**P < 0.01). Moreover, a marked accumulation of cells with 8N DNA indicated aberrant mitosis in 
HB-EGF siRNA transfected HMEC compared to negative siRNA transfectants (*P < 0.05). Data represent mean 
± SD of three independent experiments. (c) Extracellular LO activity in the conditioned media of HB-EGF RNAi 
transfectants was significantly higher than in the respective media of negative siRNA transfected HMEC (*P < 0.05 
and **P < 0.01), demonstrating elevated cross-linking activity after down-modulation of HB-EGF. Data represent 
mean ± SD of three independent experiments. 
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Thus, HB-EGF RNAi revealed the membrane-associated growth factor as an additional effector 
associated with downstream intracellular tropoelastin regulation in HMEC. Decreased HB-EGF 
signal transduction caused a reduced Fra-1 activation which in turn abolished inhibition of 
tropoelastin transcription in senescent HMEC. 
 
3.5.4 Localization of MMP-7 and HB-EGF in HMEC 
The present data suggested MMP-7 downstream signaling mechanisms via extracellular activation 
of the growth factor HB-EGF and subsequent intracellular Fra-1 induction. In order to verify 
this hypothesis, immunofluorescence analysis was used to reveal the cellular localization of the 
proteinase and the growth factor, depending on the age of the cells. HMEC were harvested in 
P12, P14 and P16 and processed for immunostaining. The DNA-intercalating dye Hoechst 33258 
visualized the appropriate nuclei in each cell (Figure 26). In young HMEC P12, both MMP-7 as 
well as HB-EGF were predominantly concentrated around the cell body (Figure 26). Moreover, 
the merged fluorescence images confirmed a co-localization of MMP-7 and HB-EGF in small, 
proliferating HMEC, displaying a circled position at the rim of the cell body (Figure 26, arrows). 
HMEC P14 represented a mixed population of smaller cells and cells significantly increased in 
cell size compared to P12. Thus, MMP-7 and HB-EGF expression represented both the 
characteristic circled localization around the cell body in smaller cells, resembling the position in 
HMEC P12, and a more spread distribution on the cell surface of enlarged HMEC (Figure 26, 
arrowhead). This diffuse location of MMP-7 and HB-EGF was further strengthened in the 
senescent P16 population, demonstrating little if any co-localization of these two proteins (Figure 
26, arrowheads). Furthermore, MMP-7 exhibited a distinct punctuate staining in the nuclear 
compartment of senescent HMEC P16 (Figure 26, double-headed arrows).  
Cellular senescence of HMEC was accompanied by a decreasing MMP-7 expression. Induction 
of down-regulated MMP-7 protein levels in young HMEC triggered an accelerated aging in these 
cells, indicating the importance of this extracellular metalloproteinase for HMEC. Moreover, 
reduced MMP-7 involved an impaired HB-EGF downstream signaling via the transcription 
factor Fra-1 which in turn resulted in activation of tropoelastin mRNA transcription. Interaction 
of the proteinase MMP-7 with the membrane-bound growth factor HB-EGF was confirmed by 
immunofluorescence analysis in young HMEC, whereas co-localization vanished in senescent 
HMEC. 
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Figure 26: Co-localization of MMP-7 and the growth factor HB-EGF. 
Immunofluorescence analysis during cellular senescence of HMEC P12, P14 and P16 exhibited a predominant 
localization of the proteinase MMP-7 and the growth factor HB-EGF at the plasma membrane of the cells. The 
nuclei became visual using Hoechst 33258 and MMP-7 and HB-EGF were detected by monoclonal mouse anti-
MMP-7 (red) and polyclonal goat anti-HB-EGF (green), respectively. Whereas young, proliferating HMEC revealed 
a characteristic co-localization of these two proteins at the rim of the cell body (arrow), enlarged senescent HMEC 
demonstrated a diffuse pattern of MMP-7 and HB-EGF (arrowhead), indicating a reduced interaction of the 
proteinase with the growth factor. In addition, MMP-7 exhibited a distinct punctuate staining overlayed with the 
nuclear compartment (double-headed arrow) (magnification 200x). 
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4 Discussion 
4.1 Post-selection HMEC encounter agonescence 
Cultured primary HMEC have a limited number of cell divisions and acquire distinct 
morphological changes with increasing culture period. The formation of long cytoplasmic 
processes and a considerable increase in cell size are accompanied by substantial intra- and 
extracellular alterations. Qualitative and quantitative analysis of p16INK4a levels in different HMEC 
populations demonstrated that neither young proliferating HMEC P12 nor senescent 
HMEC P16 expressed this cell cycle inhibitor. This characterizes these populations to be in the 
post-selection phase (Yaswen and Stampfer, 2002). Activity of SA β-gal in these post-selection 
HMEC was dramatically intensified in HMEC P16 to more than 80%, suggesting HMEC P16 as 
senescent, growth-arrested populations which eventually encounter agonescence (Figure 3). For 
simplicity, in the following HMEC P12 are referred to as young HMEC and HMEC P16 are 
designated senescent HMEC.  
As demonstrated by cell cycle analysis, cellular senescence of HMEC was associated with a 
gradually decreasing number of cells with 2N DNA but an accumulation of cells with 4N DNA. 
Besides cells arrested in the G2 phase, these results could also indicate HMEC with a tetraploid 
DNA content that arrest in the G1 phase (Sandhu et al., 2000). It was shown that cells exposed to 
DNA damage can overcome the G2 control checkpoint and proceed into mitosis. Due to the 
high risk for cells entering the M-phase with damaged DNA such as double strand breaks, these 
cells try to avoid missegregation and omit cytokinesis, resulting in binucleated tetraploid cells 
which subsequently traverse into G1 phase and are subjected to the G1 checkpoint control, 
inhibiting further S phase transition (Andreassen et al., 2001). As binucleation could be observed 
as a natural process during cardiac development, senescent cells might utilize these mechanisms 
to terminate mitosis and traverse into G1 phase (Soonpaa et al., 1996). The appearance of cells 
with an 8N DNA content in the senescent HMEC population suggested, at least for a few cells, 
further cell cycle progression. Probably owing to improper G1 checkpoint functions, some 
tetraploid HMEC might overcome this control and start again DNA replication without cell 
division, which eventually leads to 8N DNA cells (Huang et al., 2005).  
Whereas stasis, the first proliferation barrier in HMEC, is stress-associated and mediated by 
induction of the CDK-inhibitor p16INK4a, the agonescent state is characterized by dysfunctional 
telomeres inducing the DNA damage response (Figure 2, Figure 3). In general, DNA damage 
stimulates p53 which in turn activates the expression of the CDK-inhibitor p21Cip1 (Jackson and 
Pereira-Smith, 2006). However, previous studies demonstrated that senescent HMEC are not 
susceptible to p53-induced cell cycle inhibition by p21Cip1, as HMEC reaching agonescence 
exhibit invariable expression levels of this inhibitor (Sandhu et al., 2000; Romanov et al., 2001). 
Moreover, post-selection HMEC lost expression of the CDK-inhibitor p16INK4a, which as well 
contributes to an improper G1 checkpoint control (Figure 1). In addition to the regulation 
through these inhibitory proteins, cell cycle progression and CDK activity are influenced by the 
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Cdc25 phosphatase family (Nilsson and Hoffmann, 2000). Indeed, inhibition and degradation of 
Cdc25A in senescent HMEC was shown to trigger CDK2/cyclin E inactivity at the 
G1 checkpoint (Sandhu et al., 2000) and impaired CDK-dephosphorylation may contribute to the 
regulation of a cell cycle arrest in senescent HMEC. 
Senescent HMEC cease proliferation but remain in a viable, active state and last in a permanent 
growth arrest. Moreover, several studies demonstrated that many cell types underlying senescence 
become resistant to various apoptotic signals, suggesting that certain cellular pathways regulate 
the decision about cell death and elimination or permanent exit from the cell cycle but inability to 
die (Chen et al., 2000; Marcotte et al., 2004; Murata et al., 2006). Functional alterations including 
interference with apoptotic pathways in senescent cells might confer upon them a reduced 
susceptibility to certain suicide signaling (Chen et al., 2000; Marcotte et al., 2004). Thus, resistance 
to apoptosis in senescent fibroblasts is probably associated with the lack of essential pro-
apoptotic proteins such as caspase-3, while anti-apoptotic factors (e.g. Bcl-2) are maintained at 
high levels (Chen et al., 2000; Marcotte et al., 2004). Likewise, another mediator of apoptosis, the 
death-associated protein 3 (DAP3), demonstrated reduced levels in senescent cells, effecting 
resistance to oxidative stress (Murata et al., 2006). However, whereas senescent fibroblasts sustain 
a variety of apoptotic signals compared to the corresponding younger populations, senescent 
endothelial cells derived from the umbilical cord (HUVEC) are more prone to the induction of 
cell death and rather acquire a pro-apoptotic phenotype (Hampel et al., 2004). Thus, cellular 
senescence cannot be equated with resistance to apoptosis but might provide many cell types 
with functional alterations required to suppress distinct apoptotic signaling pathways and to 
maintain viability. The detailed mechanisms involved in an insusceptibility of HMEC to diverse 
cell death signals, causing long term viability and eventual accumulation in the organism, have to 
be elucidated.  
 
4.2 Cell surface-associated proteins 
Epithelial cells express a variety of cell surface proteins involved in cell-ECM adhesion, 
migration, intercellular communication, cytokine and growth factor presentation as well as 
intracellular downstream signal transduction. Interestingly, cellular senescence of HMEC was 
associated with significantly decreased levels of selected cell surface proteins (CD24, CD44, 
CD227) when comparing young versus senescent HMEC. Expression of the β1-integrin family 
member CD29, however, appeared to be unrelated to the HMEC aging process.  
The uniformly expressed CD29 functions as β1-subunit of a variety of heterodimeric cell surface 
integrins. Together with the α5-subunit, CD29 forms an essential cell surface receptor for 
fibronectin, required for fibronectin-matrix assembly and involved in cell migration processes 
(Zhang et al., 1993). Moreover, β1-integrins can interact with the ECM proteins fibrillin-1 and 
EMILIN-1, thereby supporting microfibril formation but also relaying extracellular alterations to 
cell behavior and downstream intracellular signaling pathways (Bax et al., 2003; Spessotto et al., 
2003). Other studies demonstrated a relation of an increased β1-integrin expression to the MMP-
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9-associated induction of senescence in medulloblastoma cells, but apparently this had no effect 
in the aging of mammary epithelial cells (Bhoopathi et al., 2008). 
CD227 (MUC1) is aberrantly expressed on numerous epithelial malignancies, including breast 
cancer cells, and therefore is investigated as a new tumor marker and a potential therapeutic 
target (Singh and Bandyopadhyay, 2007). Indeed, about 100% of the MCF-7 breast cancer cells 
exhibited MUC1 expression in contrast to a significantly reduced population of young HMEC 
and a further decline during HMEC senescence. MUC1 belongs to the family of mucins and 
represents a large transmembrane protein with several isoforms due to multiple alternative 
splicing as well as different proteolytical cleavages. It is composed of a heavily glycosylated 
extracellular domain and a tyrosine-rich cytoplasmic tail, which is involved in a variety of 
intracellular signal transduction processes (Ahmad et al., 2007). In addition to the overexpression 
of MUC1 on tumor cells, the glycosylation pattern differs significantly from that on non-
tumorigenic breast epithelial cells (Singh and Bandyopadhyay, 2007). Following ectodomain 
shedding and secretion, the extracellular part of MUC1 confers tumorigenic epithelial cells with 
an immune-suppressive function via growth inhibitory effects on T cells (Chan et al., 1999). 
MUC1 protects the EGF receptor ErbB1 against degradation and rather induces its recycling. 
This entails significantly increasing levels of cellular ErbB1 and might as well contribute to cell 
transformation (Pochampalli et al., 2007). Moreover, extracellular MUC1 can bind to ICAM-1 
(intercellular adhesion molecule-1) on adjacent cells and induces an intracellular signaling cascade 
which triggers cytoskeleton reorganization and migration (Shen et al., 2008). The cytoplasmic 
domain of MUC1 plays a crucial role in NFκB-activation (Ahmad et al., 2007). Intracellular 
binding of MUC1 to IKK-β stimulates phosphorylation and degradation of the NFκB inhibitor 
IκB, thereby implicating release and activation of NFκB. Whereas under physiological conditions, 
MUC1 is an important regulator of IKK-β, overexpression of this glycoprotein causes persistent 
NFκB-activation and confers the malignant cells with an anti-apoptotic mechanism (Ahmad et 
al., 2007). Whereas overexpression of MUC1 on MCF-7 cells is in concert with the tumorigenic 
phenotype of these cells, reduced MUC1 levels in HMEC and a further down-regulation during 
senescence may demonstrate a decreased tumorigenic potential in the aging cells. 
CD24, whose expression was reduced upon senescence in HMEC, is a small, heavily glycosylated, 
extracellular protein anchored by a GPI-link to the cell surface. This glycoprotein is typically 
expressed on B cells, but also represents an important function for a variety of epithelial tumors, 
including breast cancer (Lim, 2005; Schabath et al., 2006). CD24 is a known ligand of P-selectin, 
a cell adhesion molecule on endothelial cells and platelets, and thus, is suggested to enhance the 
metastatic potential of malignant cells by mediating rolling of tumor cells on endothelial cells 
(Friederichs et al., 2000; Lim, 2005). The metastasis promoting character of CD24 is augmented 
by its regulatory role concerning the function of the chemokine receptor CXCR4 (Schabath et al., 
2006). Cellular migration mediated by the chemokine CXCL12 and subsequent activation of 
CXCR4 was significantly reduced when CD24 was expressed. Moreover, loss of CD24 in breast 
cancer cells induced an increased tumor formation in mice (Schabath et al., 2006). Whereas these 
data seem contrary claiming both abundant CD24 as well as low CD24 expression to be involved 
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in solid tumor formation and metastatic developments, recent studies identified breast cancer 
cells with a stem cell-like character, expressing low to undetectable CD24 levels (Ponti et al., 
2005). This suggests that either high or negligible CD24 expression confers the cell with tumor-
promoting functions, while normal occurrence of this cell adhesion molecule contributes to 
physiological conditions and might be associated with a non-malignant phenotype. 
Similarly, protein levels of the CD44 cell adhesion molecule decreased in aging HMEC, whereas 
it was abundantly expressed on MCF-7 breast cancer cells. Interestingly, breast cancer cells 
displaying stem/progenitor cell properties are not only characterized as CD24neg./low, but also 
express high levels of CD44 (Ponti et al., 2006; Liu et al., 2007). CD44 represents a group of 
multistructural and multifunctional transmembrane heparan sulfate proteoglycans (HSPG) 
generated due to alternative splicing and different glycosylations and glycosaminoglycations 
(Naor et al., 1997). These CD44 variants interact with a large number of extracellular and 
intracellular proteins and are implicated in diverse cellular processes. The specific isoform 
CD44v3 recruits MMP-7 to the cell surface of epithelial cells (Yu et al., 2002). Simultaneously, 
binding of HB-EGF to CD44 heparan sulfate chains ensures localization of the proteinase in 
close proximity to its substrate. Interference of CD44 with ErbB1 and ErbB4 eventually allows 
binding of the activated growth factor with its receptors and subsequent signal transduction (Yu 
et al., 2002). Thus, decreased expression of CD44 in senescent HMEC could affect the 
interaction between MMP-7 and HB-EGF and thus might as well be responsible for the impaired 
HB-EGF downstream signaling in this cell population. However, further investigations are 
necessary to determine the expression of specific CD44 isoforms at the cell surface of HMEC. 
Thus, a potential role of CD44 during the aging process of HMEC and dysfunctional MMP-7 
signaling could be verified. 
Cell surface receptors involved in cellular adhesion as well as inter- and intracellular 
communication may be crucial for the function and motility of both young proliferating HMEC 
as well as tumor cells, whereby decreased levels in the senescent HMEC population may reflect 
their transition to a growth-arrested state associated with an altered signal transduction. 
 
4.3 MMP-7 is involved in the aging of HMEC 
4.3.1 MMP-7 induces an accelerated senescence in HMEC 
MMPs represent an important enzyme family of the extracellular compartment. Due to their 
versatile functionality, MMPs regulate several physiological processes; however, small 
interferences might implicate deleterious consequences for the cell itself and the surrounding 
tissue.  
Investigation of MMP-1 (interstitial collagenase), MMP-2 (gelatinase A) and MMP-9 
(gelatinase B) expression during cellular senescence of HMEC demonstrated that these proteases 
were not affected by the aging process and revealed unvarying protein levels of both their latent 
and active forms. However, proMMP-7 was slightly diminished in senescent HMEC and this was 
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even more pronounced by the active enzyme form, which was reduced below detection level in 
the senescent population, indicating a potential role of this extracellular proteinase during 
senescence of HMEC. Indeed, down-modulation of MMP-7 by RNAi had a strong impact on 
young HMEC and induced an accelerated aging in these cells. In contrast, MCF-7 breast cancer 
cells were unaffected by the reduced MMP-7 levels, suggesting that the immortalized cell line 
carries certain genetic manipulations that overcome MMP-7-induced senescence. 
Besides its originally described function in degradation and remodeling of the ECM structure, 
MMP-7 acts upon several other extracellular matrix molecules involved in cellular reorganization 
and locomotion (Wilson and Matrisian, 1996). Thus, reduced MMP-7 levels in aging HMEC 
would conversely imply restrained cell motility. Due to its broad substrate specificity against 
ECM components (e.g. collagen, elastin, fibronectin, laminin and proteoglycans) MMP-7 
prepares and allows penetration of cells through the matrix (Wilson and Matrisian, 1996). In 
addition, MMP-7 proteolysis can loose cellular aggregations and cell-matrix attachment to induce 
cell migration. Ectodomain shedding of E-cadherin by MMP-7 likewise impairs intercellular 
connections and promotes migration in association with both physiological wound healing but 
also metastasis and invasion (Noe et al., 2001; McGuire et al., 2003). Extracellular cleavage of E-
cadherin by MMP-7 is additionally associated with an intracellular disruption of the E-
cadherin/β-catenin complex, leading to release and nuclear translocation of β-catenin, which 
eventually transactivates the expression of diverse proteins, including MMP-7 (Crawford et al., 
1999; Noe et al., 2001). Thus, decreased MMP-7 activity not only causes diminished cell motility 
but also results in less transcriptional activation of its own promoter region, which would 
potentiate MMP-7 down-regulation by a negative feedback loop. Consequently, down-
modulation of MMP-7 by RNAi in young HMEC may inhibit essential intercellular and cell-ECM 
communications which are required for cellular growth and physiological functions.  
Interestingly, mice deficient in MMP-7 demonstrated significantly decreased apoptotic events 
than the control group (Powell et al., 1999), which would be in concert with the restricted 
response to certain apoptotic signals in senescent cells, also observed in HMEC (cp. 4.1, Figure 
11) (Yaswen and Stampfer, 2002). MMP-7 plays an essential role in extracellular cleavage of the 
Fas death receptor ligand FasL by generating soluble FasL (sFasL), and thereby, represents an 
important mediator of epithelial cell apoptosis (Powell et al., 1999; Vargo-Gogola et al., 2002a).  
Besides cleavage of structural ECM, the probably most important function of MMP-7 is the 
capability of growth factor activation and release of signaling molecules. Consequently, decreased 
MMP-7 levels in senescent HMEC or rather down-modulation of MMP-7 by RNAi would 
implicate a significantly reduced frequency of growth factors, and thus, diminished cell growth, 
whereas no comparable effects were observed in the tumorigenic MCF-7 breast cancer cells. 
MMP-7 demonstrates strong proteolytic activity against all six known IGF-binding proteins 
(IGFBP), thereby regulating the bioavailability of IGFs in the microenvironment and stimulating 
cell proliferation and survival (Nakamura et al., 2005). Moreover, direct cleavage of PGs by 
MMP-7 interferes with the PG-binding capacity and provokes the release of signaling molecules 
(Wight et al., 1992). The PG decorin functions as an extracellular reservoir for TGF-β, whereas 
Discussion 
 
75 
 
MMP-7-mediated degradation of decorin enhances the activation of this cytokine (Imai et al., 
1997). Involvement of TGF-β in cell cycle arrest and apoptosis suggests another possible 
mechanism  that may support apoptotic resistance in senescent HMEC (Mimori et al., 2004). 
Furthermore, binding of MMP-7 to the HSPG CD44 anchors the proteinase on the cell surface 
and subsequently assists processing of the growth factor HB-EGF to its soluble active form 
(sHB-EGF) (Yu et al., 2002). Simultaneous recruitment of ErbB1 and ErbB4, respectively, brings 
the activated growth factor in close proximity to its receptors and ensures precise and efficient 
signal transduction in a non-diffusible manner. MMP-7-catalyzed release of HB-EGF and 
subsequent transactivation of ErbB4 and ErbB1 marks a crucial mechanism involved in cell 
proliferation as well as tumor cell growth (Yu et al., 2002; Cheng et al., 2007; Lynch et al., 2007; 
Xie et al., 2009) and might as well be influenced during cellular senescence of HMEC. 
These MMP-7-associated mechanisms display only a selection of multiple pathways affected by 
this extracellular proteinase, which is even more potentiated by the ability of MMP-7 to activate 
other proteinases, including MMP-1, MMP-9 and ADAM28, resulting in the initiation of 
additional signaling cascades (Imai et al., 1995; Mochizuki et al., 2004; Page-McCaw et al., 2007). 
The involvement of this ECM protease in cellular senescence suggested an essential impact of 
extracellular signaling mechanisms and the surrounding microenvironment on the aging of 
HMEC. However, further investigations are required to identify the detailed mechanisms of 
MMP-7 activity and to eventually reveal its role in the aging process.  
 
4.3.2 MMP-7/HB-EGF co-localization in young HMEC but nuclear localization of 
MMP-7 in the senescent HMEC population 
Localization studies of MMP-7 and HB-EGF revealed a co-localization of both proteins in young 
HMEC, whereas cellular senescence was accompanied by a more diffuse spreading of HB-EGF 
which did not co-localize anymore with MMP-7. These findings indicated a possible interaction 
of MMP-7 with HB-EGF in young HMEC, which decreased in the senescent cells in conformity 
with the protein expression data. Furthermore, the senescent HMEC population displayed a 
defined intracellular localization of MMP-7 in close proximity to the nucleus. Whereas a specific 
role for intracellular or nuclear MMP-7, respectively, has not been described so far, MMP-2 and 
MMP-3 were also shown to localize to the nucleus and thereby confer a pro-apoptotic function 
(Kwan et al., 2004; Si-Tayeb et al., 2006). Both nuclear proteinases demonstrated catalytic activity 
and MMP-2 was suggested to be implicated in the degradation of PARP-1 (poly(ADP-ribose) 
polymerase-1), a protein involved in DNA repair and apoptosis (Kwan et al., 2004).  As little if 
any cell death was detected in the senescent HMEC populations, this would exclude a similar role 
for nuclear MMP-7 during HMEC senescence. For MMP-3, an essential nuclear localization 
signal (NLS) was identified that ensures a directed MMP-3 transport into the nucleus (Si-Tayeb et 
al., 2006). Thus, the nuclear appearance of MMP-7 could also result from an unknown NLS that 
triggers the retrograde transport of MMP-7 from the ECM back into the cell. On the other hand, 
increased intracellular MMP-7 levels could arise from a diminished extracellular MMP-7 transfer 
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after protein synthesis. Thus, previous data verified the necessity of the MMP-7-binding CD44v3 
for localization of the proteinase at the cell surface. Other CD44 isoforms incapable of MMP-7-
anchorage, however, failed to direct the enzyme to the extracellular compartment and 
predominantly showed intracellular MMP-7 location (Yu et al., 2002). Thus, decreased presence 
of certain MMP-7-interacting cell surface proteins such as CD44 on senescent HMEC may 
contribute to diminished MMP-7 in the extracellular space. This is substantiated by the 
expression analysis of MMP-7 during cellular senescence, demonstrating only slightly reduced 
protein levels of latent MMP-7, whereas the active form of the enzyme, which is typically 
processed at the cell surface, dramatically decreased in the senescent population. The precise 
localization of MMP-7 in senescent HMEC and its specific function in the different cellular 
compartments needs further examination. 
 
4.3.3 Down-regulation of MMP-7 and an impaired HB-EGF signaling are associated 
with elevated tropoelastin levels in senescent HMEC 
As indicated by the crucial role of MMP-7 in HB-EGF growth factor activation (cp. 4.3.1) (Yu et 
al., 2002), expression analysis revealed significantly reduced levels of this growth factor during 
senescence of HMEC. Conversely, examination of proteins involved in ECM formation such as 
tropoelastin and lysyl oxidases demonstrated a markedly increased expression in senescent cells, 
which was in concert with the detection of an enhanced appearance of elastin-like structures.  
In order to verify the potential relationship between the decreased expression of MMP-7 or HB-
EGF and the enhanced tropoelastin levels during HMEC senescence, both signaling pathways 
were targeted by RNAi. Remarkably, upon down-modulation of MMP-7, young HMEC in P12 
already exhibited an elevated tropoelastin expression when compared to the control cells. A 
similar effect was observed after siRNA targeting of HB-EGF in young HMEC, revealing 
increased tropoelastin levels in the transfectants. Expression analysis of the transcription factor 
Fra-1 revealed significantly diminished protein levels in senescent HMEC. Interestingly, down-
regulated Fra-1 levels could also be mediated by impaired MMP-7 signaling as well as upon HB-
EGF RNAi.  
Previous work demonstrated Fra-1 up-regulation to be responsible for tropoelastin inhibition 
(Rich et al., 1999), suggesting downstream signaling via Fra-1 as one potential mechanism that 
triggers tropoelastin expression in HMEC. Fra-1, also termed FOSL1 (Fos-like antigen-1), is a 
leucine zipper protein and belongs to the Fos family of transcription factors. It can dimerize with 
members of the Jun transcription factor family to form one of the AP-1 heterodimers (Rich et al., 
1999). Fra-1 can be induced upon EGF receptor signaling via downstream activation of the 
mitogen-activated protein (MAP) kinases cascade (Zhang et al., 2005). Thus, transactivation of 
the EGF receptor confers intracellular phosphorylation via the MAP kinases MEK1/2 and 
ERK1/2 (Figure 27). Activated ERK1/2 can directly phosphorylate Fra-1 in the cytosol or in the 
nucleus after ERK1/2 translocation. Phosphorylation of Fra-1 implicates a significant increase of 
its DNA-binding ability (Gruda et al., 1994) and together with a binding partner of the Jun 
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transcription factor family, Fra-1 forms an AP-1 transcription complex (Figure 27). This either 
induces autoactivation of the fra-1 gene or binds within the tropoelastin promoter and thereby 
inhibits tropoelastin transcription (Rich et al., 1999; Carreras et al., 2001). Another potential 
mechanism involves ERK1/2-mediated activation of the transcription factor Elk-1 that in turn 
binds the Fra-1 promoter and stimulates Fra-1 transcription (Carreras et al., 2001) (Figure 27). 
More recently, a similar mechanism, including ERK1/2 and Fra-1, was validated in response to 
sHB-EGF and the growth factor was shown to be responsible for reduced tropoelastin levels in 
pulmonary fibroblasts (Liu et al., 2003b). Conversely, an attenuated EGF receptor-mediated 
MAPK-signaling cascade was shown to be associated with an elevated tropoelastin expression 
and an up-regulated elastin formation (Rich et al., 1999).  
Decreased amounts of enzymatically active MMP-7 at the cell surface of senescent HMEC would 
thus imply less shedding and release of active sHB-EGF which in turn suggests a diminished 
transactivation of ErbB4 and ErbB1, respectively (Figure 27). Consequently, inhibition of the 
receptor-associated downstream signaling reduces Fra-1 accumulation in the nucleus and may 
then allow transcription of the tropoelastin gene during cellular senescence of HMEC. 
Concomitant up-regulation of LOX and LOXL1 as well as a considerably increased LO enzyme 
activity in the senescent HMEC population could contribute to an increased elastin fiber 
formation during cellular senescence. Comparably, tropoelastin stimulation after HB-EGF down-
modulation in young HMEC was accompanied by enhanced LO activity, indicating certain 
associations of induced tropoelastin precursor expression with an initiation of the maturation to 
elastin fibers.  
In addition to the induction of tropoelastin transcription, hindered HB-EGF signal transduction 
following RNAi implicated aberrant mitosis and apoptosis-promoting effects. As demonstrated 
by cell cycle analysis, HB-EGF siRNA transfectants exhibited an elevated amount of cells with an 
8N DNA content and a significant population that underwent DNA degeneration. Whereas 
overexpression of HB-EGF is associated with tumorigenesis and bears growth-inducing effects, 
down-regulation of HB-EGF causes restrained ErbB1 phosphorylation and a substantial increase 
of cell death in colon cancer cells (Ongusaha et al., 2004; Wang et al., 2007). Besides signal 
transduction via extracellular binding to ErbB4 and ErbB1, HB-EGF is capable of intracellular 
signaling involving its cytoplasmic C-terminal fragment (CTF) which bears cell cycle-promoting 
functions (Toki et al., 2005; Shimura et al., 2008). In order to verify a potential role of the CTF 
during HMEC senescence additional experiments have to address this question. 
Taken together, the present findings substantiated the importance of MMP-7 for the aging 
process of HMEC and suggested ectodomain shedding of HB-EGF as one crucial mechanism to 
relay intracellular downstream signaling via Fra-1 to transcriptional regulation of tropoelastin. 
Attenuated HB-EGF signaling provoked decreased Fra-1 levels which acts as a transcriptional 
repressor of tropoelastin and in turn, allowed tropoelastin expression.  
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Figure 27: Schematic overview of a potential mechanism involved in MMP-7/HB-EGF-mediated 
tropoelastin regulation via Fra-1  
Extracellular cleavage of proHB-EGF by MMP-7 generates active soluble sHB-EGF that in turn interacts either with 
ErbB4 or ErbB1. Autophosphorylation of the ErbB4/1 receptor transduces an intracellular signaling cascade 
implicating the MAP kinases MEK1/2 and ERK1/2. ERK1/2 can directly phosphorylate Fra-1 in the cytosol or 
after its translocation in the nucleus, which significantly improves Fra-1 DNA-binding activity. Fra-1 associates with 
a transcription factor of the Jun family to form one of the AP-1 heterodimers that either autoactivates the fra-1 gene 
or binds within the tropoelastin promoter and thereby inhibits tropoelastin transcription. In addition, ERK1/2 
activates the transcription factor Elk-1 which as well induces gene transcription of Fra-1. However, attenuated 
MMP-7 activity in senescent HMEC would cause a decreased proHB-EGF shedding and thus less sHB-EGF. 
Restrained ErbB4/1 activation subsequently impedes MAP kinase signaling and prevents Fra-1 DNA-binding, which 
in turn allows access to the promoter region of the tropoelastin gene and leads to increased tropoelastin expression. 
(For a detailed scheme illustrating tropoelastin trafficking see Figure 4). 
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4.3.4 MMP-7 bears elastolytic enzyme activity 
Apart from affecting downstream signaling pathways, MMP-7 has a broad substrate specificity 
against ECM components, including a potent elastolytic activity (Wilson and Matrisian, 1996). 
This suggested that reduced MMP-7 activity in senescent HMEC may hinder elastin degradation 
and thereby reinforces elastin occurrence. Indeed, MMP-7 represents one of the most effective 
metalloproteinases capable of elastin cleavage and for example confers macrophages with a 
proficient elastolytic system associated with physiological and pathological matrix degradation 
(Mecham et al., 1997; Filippov et al., 2003). In addition to its regulatory function related to 
tropoelastin gene transcription, diminished MMP-7 activity may also restrain degradation of the 
mature elastin fiber. However, further experiments are required to evaluate the elastolytic role of 
MMP-7 during cellular senescence of HMEC. 
 
4.4 Impact of the ECM and alterations of the microenvironment on cellular 
behavior 
4.4.1 Increased elastin formation in the senescent HMEC population contributes to an 
altered extracellular microenvironment 
The extracellular microenvironment has an important impact on the development and function 
of a cell, which includes the initiation of extracellular-triggered signaling mechanisms as well as 
the composition of the extracellular matrix. The present study revealed that progression of 
cellular senescence in HMEC is accompanied by an increased intracellular tropoelastin expression 
followed by enhanced extracellular elastin fiber formation. Alterations in the biosynthesis of 
ECM macromolecules were shown to play a crucial role in biological aging and age-related 
disease as well as malignant transformation (Labat-Robert and Robert, 2007; Marastoni et al., 
2008). In tissues such as lung, skin and blood vessels, elastin biosynthesis exclusively occurs early 
in life and the aging process is rather associated with progressive degeneration of the elastin 
matrix, causing dysfunctional tissue (Bouissou et al., 1988; Bruce and Honaker, 1998; Pezet et al., 
2008). Whereas these effects may be tissue-specific, other work compared healthy breast tissue 
specimens of young and elderly women and revealed excessive elastin fibers predominantly 
around the ducts of more than 50% of women over age 50, whereas this phenomenon was not 
observed in young women (Farahmand and Cowan, 1991). According to these findings, a 
prominent appearance of elastic tissue in the breast was proposed to be involved in a 
precancerous development (Jackson and Orr, 1957; Azzopardi and Laurini, 1974). Whereas 
primary studies exclusively considered stromal cells to be capable of elastin formation 
(Lundmark, 1972; Tremblay, 1976), there is increasing evidence that epithelial cells themselves 
generate newly synthesized elastic fibers (McCullagh et al., 1980; Krishnan and Cleary, 1990) 
which is also supported by our results. Altered cell matrix interactions and modified ECM 
components have been proposed to play a crucial role in tumor formation and metastatic 
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developments (Labat-Robert and Robert, 2007; Ingber, 2008). Thus, it is notable that tumor cells 
not only affect normal ECM biosynthesis by stimulation of adjacent fibroblasts but themselves 
are able to produce elastic fibers (Kadar et al., 2002; Lapis and Timar, 2002). Considering an 
accumulation of senescent cells in the aging tissue, an increased elastin formation of senescent 
HMEC may thus provide a microenvironment in the aged breast which might favor malignant 
transformation. However, ECM formation, composition and architecture are determined by a 
complex interplay of a multifactorial regulatory system, whereof the particular mechanisms are 
still obscure. Additional investigations are required to assess the impact of the extracellular 
microenvironment and to understand influences of modified ECM components in relation to 
tumor formation and cancer progression. 
 
4.4.2 Increased LOXL1 expression in senescent HMEC contributes to an enhanced 
elastic fiber formation  
Post-translational processing by lysyl oxidases plays a key role in elastin fiber formation and 
provides structural shape to the ECM (Liu et al., 2004; Szauter et al., 2005). Lysyl oxidases are 
multifunctional proteins whose deregulation contributes to a variety of pathological 
developments including fibrotic processes, neurodegenerative disorders as well as tumor 
progression and metastasis (Rodriguez et al., 2008). Recent investigations revealed LOXL1 as an 
essential factor in normal elastin synthesis, and moreover, suggested an important role for this 
isoform in adult elastin maturation (Liu et al., 2004; Behmoaras et al., 2008), which is also 
supported by the present data. During cellular senescence of HMEC, the enhanced tropoelastin 
expression was accompanied by increased LOXL1 protein levels and an elevated lysyl oxidase 
activity, probably contributing to the high incidence of elastin fibers in senescent HMEC 
cultures. Furthermore, the direct involvement of LO enzyme activity in elastin formation during 
HMEC senescence was verified by inhibitor studies. These findings suggested an important 
function of LOXL1 to ensure further processing of the prevalent tropoelastin precursor 
molecules in senescent HMEC populations. LOXL1 knockout studies in mice substantiate an 
abnormal elastin polymerization and confirm an accumulation of dysfunctional tropoelastin 
aggregates (Liu et al., 2004). In addition to their cross-linking activity and certain scaffolding 
capacities, there is increasing evidence that lysyl oxidases are able to regulate transcriptional 
activation, migration and cell adhesion and in that way contribute to malignant cell 
transformation and cancer progression (Payne et al., 2007). Moreover, it was observed that LOX 
expression directly affects tropoelastin levels and was shown to interfere with tropoelastin 
promoter regulation (Oleggini et al., 2007). However, further experiments have to analyze the 
function of an increased LOXL1 expression with respect to potential intracellular alterations 
during cellular senescence of HMEC. 
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Figure 28: A schematic overview of elastin receptor signaling 
Interaction of elastin with EBP stimulates Neu-1 activity and involves activation of intracellular G proteins that 
impart receptor signaling to a variety of cellular pathways. Phosphorylation of FAK induces reorganization of the 
cytoskeleton and ensures cell motility. An increasing invasiveness is moreover achieved by enhanced expression and 
extracellular secretion of degrading enzymes such as MMPs and elastase. The tyrosine kinase c-Src can be stimulated 
by FAK or via G proteins and relays phosphorylation signals downstream to ERK1/2. Activated PLC cleaves 
phosphatidylinositol biphosphate (PIP2) in the plasma membrane and releases intracellular DAG and IP3 followed by 
an elevation of cytoplasmic Ca2+ ions and translocation of PKC to the plasma membrane. Initiation of the MAP 
kinase cascade including the small GTPase Ras and ERK1/2 provokes activation of several transcription factors. 
The presence of other signaling molecules and the interaction with distinct binding-partners subsequently modulates 
transcriptional activation of genes such as CDKs and their associated cyclins or MMPs. In contrast, ERK1/2-
activation upon sHB-EGF/ErbB4/1-binding stimulates transcription of the elastin precursor tropoelastin 
(cp. Figure 27). Thus, binding of elastin to the EBP at the cell surface can affect cellular proliferation, migration, 
invasion and chemotaxis, indicating crucial aspects involved in malignant transformation and metastatic 
developments. The scheme was adapted from (Mochizuki et al., 2002). 
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4.4.3 Elastin receptor signaling 
Besides its structural function as a component of the ECM, elastin stimulates a variety of 
biological activities such as chemotaxis, proliferation and protease release (Duca et al., 2004). 
This suggests other potential mechanisms by which the senescent HMEC may influence 
susceptible adjacent cells and may favor a malignant transformation. Elastin peptides can 
specifically interact with surrounding cells via receptor-binding and thereby affect intracellular 
signal transduction pathways (Mochizuki et al., 2002). The same complex of elastin-binding 
protein (EBP) associated with neuraminidase-1 (Neu-1) and protective protein/cathepsin A (PP) 
can act on one hand as a molecular chaperone in tropoelastin trafficking (cp. 1.3.1.2 and Figure 4) 
(Hinek et al., 1995), and on the other hand, can function as a specific elastin receptor at the cell 
surface of a variety of cells types (Figure 28) (Fulop et al., 2001; Hinek et al., 2006). EBP 
represents a spliced variant of lysosomal β-galactosidase and is localized to the cell surface by 
membrane-bound Neu-1 and PP (Duca et al., 2007). Neu-1 is a member of sialidases that 
hydrolyze terminal sialic acid residues of glycoproteins, oligosaccharides and glycolipids. Whereas 
Neu-1 activity was essential for elastin peptide signaling, the serine protease activity of PP was 
not required and PP rather protects EBP and Neu-1 from proteasomal digestion (Duca et al., 
2007). Elastin binding stimulates a variety of signal transduction pathways that provoke diverse 
effects; however, the mechanisms affected by elastin receptor activation vary greatly among 
different cell types (Figure 28). Thus, binding of elastin to EBP involves intracellular activation of 
pertussis toxin-sensitive G proteins, opening of L-type Ca2+-channels and induction of several 
tyrosine kinases including c-Src, FAK, PDGF receptor kinase and the MAP kinase pathway 
(Figure 28) (Duca et al., 2004). G protein-mediated activation of phospholipase C (PLC) causes 
increase of the second messengers inositoltriphosphate (IP3) and diacylglycerol (DAG) that in 
turn lead to intracellular Ca2+ elevation and protein kinase C (PKC) activation and eventually 
relay downstream signaling via Ras to the MAP kinase pathway (Fulop et al., 2001). The elastin 
receptor-mediated initiation of the MAP kinase phosphorylation cascade via Ras – Raf-1 – 
MEK1/2 – ERK1/2 subsequently triggers expression and release of proteases such as elastase, 
MMP-1, MMP-2 and MMP-12 which contribute to matrix degradation and invasion (Fulop et al., 
2001; Duca et al., 2007; Coquerel et al., 2009). Remarkably, as shown before, the same signaling 
cascade can also activate Fra-1 which inhibits tropoelastin expression (Figure 27). However, the 
stimulation of these apparent contradictory effects might probably not be caused due to one 
distinct signal but rather depends on a complex interplay of a variety of interacting proteins. 
Thus, presence of other binding-partners and the implementation of certain threshold effects 
might be related to the preference of one or the other signaling outcome. Thus, activation of 
MAP kinases by c-Src and/or PDGF receptor was shown to be responsible for an induction of 
CDKs and their regulatory cyclins, thereby stimulating cellular proliferation (Mochizuki et al., 
2002). The focal adhesion kinase (FAK) imparts elastin receptor transduction to phosphorylation 
of cytoskeleton-associated molecules such as β-tubulin, α-actin, microtubule-associated protein-1 
light chain 3 (LC3), microtubule-associated protein 1 (MAP1) or troponin T, implicating 
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cytoskeletal reorganization (Mochizuki et al., 2002). Besides presence on non-tumorigenic cells, 
the elastin receptor was shown to be abundantly expressed on tumor cells and was related to the 
metastatic evolution of breast cancer, related to its role in migration and invasion (Fulop and 
Larbi, 2002; Lapis and Timar, 2002). Previous studies have demonstrated a progressive 
uncoupling of the elastin receptor to be reliant on age and suggested an important role in the 
development of age-associated diseases (Jacob et al., 1987; Fulop et al., 2001).  
According to the diversity of biological functions affected by the elastin receptor, an increased 
elastin occurrence during cellular senescence of HMEC might as well imply potential effects on 
the senescent cell itself or through paracrine signaling on neighboring cells. However, extensive 
investigations are required to assess a possible role for the elastin receptor during senescence of 
HMEC. 
 
4.5 Conclusion 
The present data revealed significant alterations in the extracellular environment of senescent 
HMEC including down-regulation of the cell surface glycoproteins CD24, CD44 and CD227, an 
attenuated MMP-7 activity and an increased expression of tropoelastin that may contribute to an 
enhanced elastic fiber generation in the senescent HMEC population. Down-modulation of 
MMP-7 in young HMEC induced an accelerated aging, and thus, verified a direct involvement of 
this metalloproteinase in the aging process of HMEC. Besides extracellular effects due to reduced 
matrix degradation, MMP-7 down-regulation can affect a variety of intracellular signaling 
mechanisms. Localization studies revealed a co-localization of MMP-7 with the growth factor 
HB-EGF in young HMEC but a diffuse distribution in the senescent population. The reduced 
interaction between MMP-7 and HB-EGF could be related to the decreased expression of CD44 
at the cell surface of senescent HMEC. However, supplementary analyses that specify the 
different CD44 variants, particularly variant 3, are required to evaluate a potential role of CD44 in 
MMP-7/HB-EGF cell surface anchorage.  
Further experiments demonstrated that reduced MMP-7 and diminished HB-EGF affected 
downstream signals that caused decreased levels of the transcription factor Fra-1, which resulted 
in an increased tropoelastin transcription. Moreover, the activation of tropoelastin expression 
may favor the LO-dependent elastin maturation in the extracellular matrix of senescent HMEC. 
Examination of the elastin receptor status at the cell surface of senescent HMEC populations 
would be interesting to consider a potential role of elastin receptor-associated signaling pathways 
in aging HMEC. In this context, it may be speculated that an increased interaction between 
elastin and its receptor during senescence could induce expression of proliferation-promoting 
genes (e.g. CDKs and cyclins; cp. Figure 28), which in turn would contribute to an aberrant cell 
cycle progression and the generation of senescent 8N DNA HMEC. However, the particular 
signaling mechanisms and their complex interplay that regulates the cell cycle during cellular 
senescence of HMEC need to be elucidated.  
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The inhibited cell division and the enlarged cell morphology of senescent HMEC represented 
characteristics of a non-malignant cell, which was in concert with the reduced levels of the 
tumor-associated CD227 (MUC1) during senescence. Conversely, an increased presence of 
elastin was related to a potential breast cancer development. To unravel this apparent 
contradiction, the in vivo situation has to be considered. In the aging organism, senescent HMEC 
accumulate in the breast tissue, and thus, the predicted effects of elastin may not only influence 
the senescent cells themselves, but rather act on susceptible adjacent cells, whose signaling 
mechanisms are affected by additional cancer-promoting deregulations which favor their 
malignant transformation.  
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